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PLATELETS AND ANTI-ANGIOGENIC RESISTANCE IN OVARIAN CARCINOMA 
 
Publication No._____ 
Justin Neal Bottsford-Miller, M.D. 
Supervisory Professor:  Anil K. Sood, M.D. 
Background:  Resistance to targeted anti-angiogenic therapy is a growing clinical 
concern given the disappointing clinical impact of anti-angiogenic. Platelets 
represent a component of the tumor microenvironment that are implicated in 
metastasis and represent a significant reservoir of angiogenic regulators. 
Thrombocytosis has been shown to be caused by malignancy and associated with 
adverse clinical outcomes, however the causal connections between these 
associations remain to be identified. 
Materials and Methods:  Following IRB approval, patient data were collected on 
patients from four U.S. centers and platelet levels through and after therapy were 
considered as indicators of recurrence of disease. In vitro effects of platelets on 
cancer cell proliferation, apoptosis, and migration were examined. RNA interference 
was used to query signaling pathways mediating these effects. The necessity of 
platelet activation for in vitro effect was analyzed. In vivo orthotopic models were 
used to query the impact of thrombocytosis and thrombocytopenia on the efficacy of 
cytotoxic chemotherapy, the effect of aspirin on thrombocytosis and cancer, and 
platelet effect on anti-angiogenic therapy. 
Results:  Platelets were found to increase at the time of diagnosis of ovarian cancer 
recurrence in a pattern comparable to CA-125. Platelet co-culture increased 
proliferation, increased migration, and decreased apoptosis in all cell lines tested. 
RNA interference implicated platelet derived growth factor alpha (PDGFRA) and 
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transforming growth factor beta-receptor 1 (TGFBR1) signaling. Biodistribution 
studies suggested minimal platelet sequestration of taxanes. Blockade of platelet 
activation blocked in vitro effects. In vivo, thrombocytosis blocked chemotherapeutic 
efficacy, thrombocytopenia increased chemotherapeutic efficacy, and aspirin 
therapy partially blocked the effects of thrombocytosis. In vivo, withdrawal of anti-
angiogenic therapy caused loss of therapeutic benefit with evidence of accelerated 
disease growth. This effect was blocked by use of a small-molecule inhibitor of 
Focal Adhesion Kinase. Anti-angiogenic therapy was also associated with increased 
platelet infiltration into tumor that was not seen to the same degree in the control or 
FAK-inhibitor-treated mice. 
Conclusions: Platelets are active participants in the growth and metastasis of tumor, 
both directly and via facilitation of angiogenesis. Blocking platelets, blocking platelet 
activation, and blocking platelet trafficking into tumor are novel therapeutic avenues 
supported by this data. 
 
Copyright © 2012 Justin Neal Bottsford-Miller, all rights reserved. 
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Background and Introduction 
Angiogenesis 
Angiogenesis is necessary for tumor growth and progression (1). Tumors 
acquire a blood supply by varied means including vasculogenesis, co-option of 
established vasculature, and vascular mimicry (2, 3). Vasculogenesis refers to 
production of new blood vessels via infiltration of new endothelial cells in to the 
tumor. Co-option of established vasculature refers to tumor cells surrounding and 
invading established, otherwise normal and healthy vascular structures. Vascular 
mimicry refers to the phenomenon in which tumor cells take on the phenotypic 
and functional aspects of endothelial cells necessary to facilitate blood flow. 
Efforts to therapeutically target tumor angiogenesis have focused on the vascular 
endothelial growth factor (VEGF) pathway (4). VEGF targeting has shown 
promise, but it has not proven as efficacious as hoped (5, 6). Evidence supports 
the hypothesis that members of the tumor microenvironment mediate some 
mechanisms of escape from anti-angiogenesis therapy; it is thus hypothesized 
that simultaneous targeting of tumor and microenvironment may lead to improved 
clinical outcomes in the treatment of solid tumors (7, 8).  
 
Targeting Angiogenesis via VEGF 
Forty years ago, driven by the discovery that tumor-associated endothelial 
cells are foundational in tumor neovascularization, these endothelial cells were 
proposed as a therapeutic target. VEGFA was identified as a central promoter of 
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angiogenesis in general and endothelial cell survival in particular (9). Based on 
these findings, the VEGF signaling system has been targeted using both small 
molecule inhibitors and antibodies to components of the system. Bevacizumab 
(monoclonal antibody against VEGFA165) was among the earliest anti-
angiogenic agents developed, and it is currently the most advanced of VEGF-
targeted agents (10). This agent has provided clinical benefit in several types of 
solid tumors, including colorectal, renal, non-squamous/non-small-cell lung 
cancer, and glioblastoma (11). While bevacizumab was approved for metastatic 
breast cancer in 2008, the Food and Drug Administration ultimately withdrew 
approval over concerns about efficacy and toxicity (11). In ovarian cancer, 
Gynecologic Oncology Group (GOG) 218 and the Gynecologic Cancer 
InterGroup (GCIG) trial ICON7, both conducted in the front-line adjuvant setting 
following surgical tumor cytoreduction, demonstrated modest improvements in 
progression free survival (PFS) in the groups receiving maintenance 
bevacizumab. Overall survival (OS) data are not anticipated to be positive, and 
while interval to progression is improved, there appears to be no improvement in 
the total number of patients who progress (12, 13). Small molecule inhibitor data 
are less mature, but early data suggest similar concerns with respect to sorafenib 
and sunitinib (14, 15).  
 
Angiogenesis Resistance and Escape 
 As our concept of angiogenesis has matured and expanded, the 
complexity of angiogenesis with its balance of redundant and oppositional 
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systems has become more apparent (3). Evolutionary biology offers the 
perspective that disruptions in an ecologic system generated by a new selection 
pressure produce reactions that tend to stabilize the entire system; heterogeneity 
within a system will provide resilience against selection pressure. Cancer cells 
are heterogeneous, as is their microenvironment, facilitating systemic resilience 
within the whole of the tumor to selection pressures (16). Anti-angiogenic therapy 
decreases blood flow and increases hypoxia within the tumor microenvironment, 
triggering tumor cell-driven compensatory responses that have myriad 
downstream effects (17). Otherwise normal cells in the tumor microenvironment, 
e.g. endothelial cells, pericytes, platelets, fibroblasts, and white blood cells, are 
known to have healthy, regulatory functions that are co-opted to support the 
tumor. Potential mechanisms of resistance to anti-angiogenic therapy may be 
mediated by tumor cell selection directly, but microenvironmental selection 
pressure and modification is likely to play a significant role in resistance to these 
therapies.  
 
Ovarian Cancer 
Across the spectrum of human malignancy, over the past thirty years, 
SEER data suggest little progress in curbing mortality.  Specifically, considering 
all mortality in the United States from 1975-2009, age-adjusted mortality with 
respect to cancer has only decreased from 200 deaths per 100,000 people to 
175 deaths per 100,000 people over those thirty years.  
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Ovarian cancer remains the fifth leading cause of cancer death among 
women.  Approximately 21,000 American women will receive the diagnosis of 
ovarian cancer this year, and about 15,000 American women will die this year 
from this disease (18). Recurrence rates have changed little over the past thirty 
years, and recurrence remains an essentially terminal event, and as a 
consequence, disease-specific mortality has changed little over the last thirty 
years. In contrast, improvements have been seen in median survival for women 
with advanced ovarian cancer, which has increased over 18 months during the 
same thirty-year period (19). However, the absence of reliable, prospective 
screening biomarkers, it remains that disease onset is insidious, and late 
diagnosis of advanced disease remains common (20).  
Typical care for primary ovarian cancer involves some combination of 
tumor reductive surgery and 6-8 cycles of cytotoxic chemotherapy, most typically 
combined carboplatin and paclitaxel (21). While epithelial ovarian cancer tends to 
be chemo-responsive, with an induction-chemo response rate of 70-80%, 
responders have a 40-50% rate of relapse within 2 years (22). In the recurrent 
setting, salvage chemotherapy provides a 15-20% response rate with essentially 
zero cures (23-25). Considering large, modern clinical trials, women with ovarian 
cancer are estimated to have a median progression-free interval in the range of 
11-18 months and median survival duration in the range of 24-40 months, 
depending on stage of disease at diagnosis and the success of the tumor 
reductive surgery (26-28).   
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Recent prospective clinical studies have suggested that the addition of 
more cytotoxic agents the current standard of paclitaxel and carboplatin does not 
improve progression or survival outcomes (29). This disappointing outcome has 
opened the floor to alternative targets and therapeutic regimens. One compelling 
strategy includes “metronomic” dosing of chemotherapy. By this strategy, lower 
doses of cytotoxic agents are given at greater frequency. One hypothesis is that 
this dosing regimen targets more than merely tumor cells, but targets systems-
level biologic functions, including the development and maintenance of tumor 
vasculature (30, 31). Clinically, semi-metronomic, or “dose-dense,” regimens 
have shown intriguing superiority in early clinical trials to traditional dosing 
regimens (32-35). Mechanisms remain poorly characterized but suggest effects 
other than those typically considered, including microenvironmental targeting that 
may effect treatment efficacy and inform concepts of appropriate/effective 
dosing.  
The fact that we have seen limited improvement in survival outcomes for 
ovarian cancer over the past 30 years should give pause, and it raises the 
question that we may be ignoring a significant biological component of cancer 
growth and development that strongly influences treatment efficacy. Given recent 
trends toward more comprehensive consideration of the totality of tumor biology 
and interaction with its environment, we considered the question of whether 
micro-environmental factors, for example platelets, could contribute to the 
pathogenicity of cancer.  
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Platelet Development 
Megakaryopoiesis is a complex and evolutionarily conserved process.  
Nearly one billion megakaryocytes turn over in the bone marrow every day (36). 
The cell of origin is the committed myeloid progenitor cell, from which the colony-
forming unit-granulocyte-erythroid-macrophage-megakaryocyte (CFU-GEMM) 
emerges. From the population of CFU-GEMM, some will become burst-forming 
unit-megakaryoctes (BFU-Meg) that are ultimately and irrevocably committed to 
megakaryocyte differentiation.  IL-3 supports early stages of megakaryocyte 
development. Thrombopoietin (TPO) primarily regulates thrombopoiesis.  IL-6, 
IL-11, and stem cell factor (SCF) are also stimulatory, but they will only act in 
coordination with TPO and IL-3. (Figure 1) 
 
Figure 1: Schematic diagram of platelet development. The process is 
primarily driven by IL-3 and TPO and is augmented by other cytokines. 
 
Platelets average 2-5 mcm diameter and 0.5 mcm thickness.  They have 
an average lifespan of 7-10 days, requiring production of 1.0 x 1011 cells per day 
to maintain normal blood levels in humans (37). This baseline production level 
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will fluctuate substantially in response to contextual cues, including humoral 
factors resulting from malignancy (37). 
 
Platelet structure 
Electron microscopy of the platelet plasma membrane suggests a folded 
surface that would accommodate significant spreading and shape change. It also 
shows small openings in the plasma membrane connected to the canalicular 
system. In the submembrane zone, there are no formal organelles, but 
cytoskeletal structures are seen that appear to have contractile function 
dedicated to the movement and localization of receptors on the platelet surface; 
these elements appear vital to adhesion and spreading. 
Within the interior of the platelet, imaging suggests a matrix within which 
several organelle structures have been identified. What were thought to be 
circumferential coils of microtubules actually represent a single microtubule, 
coiled on itself many times like a cowboy’s lasso. Experimental evidence 
suggests that this single, coiled microtubule provides cytoskeletal support and 
facilitates pseudopod extension for platelet migration. The effect of paclitaxel on 
platelet function has been studied in this context. Specifically, platelets were 
chilled to 4oC, causing loss of disc shape, increased pseudopod extension, 
disassembly of microtubule coil, and assembly of new actin filaments, all 
consistent with migration and activation activities. Re-warming to room 
temperature reversed these changes. Paclitaxel blocked the cold-induced 
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changes and specifically limited pseudopod formation, suggesting that in theory 
paclitaxel may block platelet migration (38). 
Microfilaments participate in platelet activation and the release of platelet 
granule contents into the environment around the platelet. They are composed of 
actin filaments and make up the preponderance of the cytoskeleton. When 
platelet activation occurs, microfilaments participate in microtubule constriction 
and mobilize granules to facilitate secretion of contents via the open canalicular 
system. The open canalicular system connects the surface of the platelet to the 
entire interior of the platelet, facilitating efficient material exchange and protein 
transfer (39-42). It is this release of granule contents in which may be found an 
underappreciated nexus of angiogenesis regulation. 
Alpha-granules are the most abundant organelles.  There are typically 40-
80 alpha granules per platelet. Alpha-granules have been documented to contain 
a significant number of compounds, many of which are growth factors and 
angiogenesis modulators and are listed in Table 1.   
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Alpha-Granule Contents(43-50)  
Adhesion Molecules P-Selectin 
Von Willebrand Factor 
Thrombospondin 
Fibrinogen 
Integrin alpha-2b-beta-3 
Integrin alpha-5-beta-3 
Fibronectin 
Chemokines Platelet basic protein 
Platelet Factor 4 
CXCL4 
Beta-thromboglobulin 
MIP-1-alpha 
RANTES 
MCP-3 
CCL17 
CXCL1 
CXCL5 
IL-8 
Coagulation Pathway Factor V 
Multimerin 
Factor VIII 
Fibrinolytic Pathway Alpha-2-Macroglobulin 
Plasminogen 
Plasminogen activator inhibitor 1 
Growth Factors and Angiogenesis Basic fibroblast growth factor 
Epidermal growth factor 
Hepatocyte growth factor 
Insulin-like growth factor-1 
Transforming growth factor-beta 
Vascular endothelial growth factor-A 
Vascular endothelial growth factor-C 
Platelet-derived growth factor 
Gas6 
Immunologic Factors Beta-1-H globulin 
Factor D 
C1 inhibitor 
IgG 
Other Albumin 
Alpha-1-antitrypsin 
Histidine-rich-glycoprotein 
High molecular weight kininogen 
Osteonectin 
Protease nexin-2 
Table 1: Alpha granule contents identified to date. 
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Dense granules are smaller and less numerous than alpha-granules.  
Their contents are primarily ions and adenine nucleotides and are detailed in 
Table 2. 
 
Dense Granule Contents(51, 52)  
Ions Calcium 
Magnesium 
Phosphate 
Pyrophosphate 
Nucleotides ATP 
GTP 
ADP 
GDP 
Membrane Proteins CD63 
LAMP2 
Transmitters Serotonin 
Table 2: Dense granule contents identified to date. 
 
Platelets and Angiogenesis 
As described earlier, the regulation of angiogenesis in tumors has been an 
active area of basic and translational research for forty years (53). As early as 
the 1960’s, experimental models associated platelets with endothelial cell 
stability (54-56). Platelet co-culture was found to promote endothelial cell growth, 
and early descriptive studies suggest changes in the shape and migration of 
endothelial cells in response to platelet co-culture (57-59). 
It has since been determined that platelets sequester and release an array 
of angiogenesis-regulating agents, underscoring the reasonable hypothesis that 
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platelets are involved in angiogenic regulation and the difficulty in determining a 
total effect given such a large and diverse set of angiogenic regulators. These 
regulators are detailed in Table 3. 
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Angiogenesis 
Regulators 
 
Vascular 
Endothelial 
Growth Factor 
(VEGF)  
Angiogenesis agonists found in platelets as VEGFA (primarily 
VEGFA
165
) and VEGFC.
71
 Platelets have mRNA for VEGF
189
 and 
VEGF
121
.
72
  
Platelet-Derived 
Growth Factor 
(PDGF)  
Found in three dimer combinations of two chains (A and B).
73
  
Receptor binding results in proliferation and migration of 
fibroblasts and smooth muscle cells.
74
 
Fibroblast Growth 
Factor (FGF)  
Angiogenesis agonists FGF2 and bFGF recruit and induce 
proliferation of endothelial cells.
75,76
 
Epidermal Growth 
Factor (EGF)  
Angiogenesis agonist that induces proliferation and tube-
formation in cell lines that express the appropriate receptor.
77,78,79
 
Hepatocyte 
Growth Factor 
(HGF)  
Angiogenesis agonist via the activation of the c-met receptor, 
which is highly expressed in smooth muscle and endothelial cell 
populations.
80
  
Insulin-like Growth 
Factor (IGF)  
Both isoforms (1 and 2) are angiogenesis agonists. Receptor 
activation is pro-angiogenic.
81,82
 
Angiopoietin 
(APO) 
APO-1 is a ligand for the tyrosine kinase receptor Tie2, and 
binding is pro-angiogenic.
83
 Increased in platelets of breast cancer 
patients.
84
 
Platelet 
Phospholipids  
Molecular family with chemotactic, proliferation, and tube-
formation effects on endothelial cells.
85,86
  
CD40 Ligand and 
Platelet Activating 
Factor  
Expressed on the platelet surface following activation. Binding to 
endothelial cells is pro-angiogenic and partially mediated by 
platelet-activating factor.
87
 
Matrix 
Metalloproteinases  
Of this family of endopepidases known to facilitate cellular 
migration with angiogenesis, MMP-1, MMP-2, and MMP-9 are 
contained in platelets.
88,89
 
Heparanase  This endoglycosidase cleaves heparin sulfate, releasing 
angiogenic mediators and increasing bioavailability.
90,91
 
Angiostatin  Potent angiogenesis inhibitor released on activation.
92
 
Thrombospondin-
1 (TSP1)  
At low concentrations, TSP1 has anti-angiogenic effects. At high 
concentrations, it can mediate pro-angiogenic effects.
93,94
  
Platelet Factor 4 
(PF4)  
Angiostatic effects are driven by interference with the binding of 
and function of growth factors, e.g. FGF.
95,96
 
Table 3: Functions of angiogenesis regulators identified in platelets. 
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In the context of wound healing, angiogenesis regulation and function is 
increasingly understood include platelets, although the question of specific 
platelet function in wound healing remains controversial (60, 61). Platelets form 
plugs. Of more interest is the observation that VEGF concentration increases in 
the region of an in vivo thrombus, and VEGF derived from platelets accumulates 
within thrombus, presumably to be released as the thrombus resolves (62, 63). In 
an experimental wound model in rats, wound formation was correlated with 
increased serum VEGF and decreased endostatin. These changes in serum 
VEGF and endostatin did not occur when the animals were treated with 
ticlodipine (an inhibitor of platelet activation by ADP) or by platelet depletion (64). 
In other animal models, application of platelet-derived topical compounds to 
wounds stimulates formation of granulation tissue (65). In clinical trials, 
affirmative results have been obtained using the local, topical application of 
platelet-derived topical compounds to wounds (66-68). 
Ultimately, most experimental work on platelets with respect to 
angiogenesis has focused on endothelial cell responses. Platelet co-culture 
promotes endothelial cell proliferation and survival when those cells are 
otherwise deprived of appropriate growth factors. These effects do not require 
direct contact, but activation does appear to be required, as aspirin pre-treatment 
and fixation with paraformaldehyde both appear to block the observed effects. 
Platelets have been shown promote tube formation in human umbilical vein 
endothelial cells in a dose-dependent manner (69). The observed effects appear 
to be mediated in part by VEGF and FGF2 (70).  
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Considering the breadth of regulatory molecules in platelets, consideration 
of the sum effect of effectors becomes important. In an ex vivo rat model, pro-
angiogenic effects of platelets were substantially inhibited through blockade of 
the VEGF, bFGF, and PDGF signaling pathways (71). An in vivo mouse model 
using subcutaneous Matrigel suggested a similar spectrum of causal signaling 
and pointed to the importance of heparanase as a participant in the biology (71). 
Other investigators have specifically implicated VEGF and bFGF in platelet-
driven angiogenesis (72). Separate studies have suggested that platelet 
involvement in angiogenesis and metastasis is at least partially mediated by the 
signaling of integrin alpha-5-beta-3 between platelets and the endothelium (73). 
 
Platelets and Malignancy 
Interactions between tumor cells and the tumor microenvironment are 
increasingly recognized as key context to understand the selection pressures 
that influence the survival and propagation of clonal cell populations that manifest 
particular phenotypes such as invasion and metastasis. For instance, a dynamic 
interaction between tumor cells, fibroblasts, inflammatory cells, and bone marrow 
derived precursors has been shown to facilitate tumor cell intravasation and 
metastasis (74). 
With respect to platelets, the correlation between thrombocytosis 
(conventionally defined as >450,000 platelets per cubic millimeter of whole blood) 
and solid malignancy has been recognized for over a century and has been an 
area of intermittent research.  Recently, it was shown that tumor production of IL-
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6 caused increased hepatic production of thrombopoietin that caused increased 
megakaryocyte counts and production of platelets in the bone marrow (37). 
Correlative confirmation comes from a nude mouse model utilizing immortalized 
Chinese hamster ovarian cells, IL-6 transfection of the cells was associated with 
elevating circulating IL-6 in vivo, hypercalcemia, leukocytosis, thrombocytosis, 
and decrease in body weight compared to animals bearing non-transfected tumor 
(75). 
The biological significance of this correlation has been more elusive, 
however several studies have suggested that elevated platelet counts in cancer 
are associated with adverse prognosis (37, 76, 77). As early as the 1960’s, an 
experimental model supported a direct link between thrombocytosis and 
metastasis (78). It was first demonstrated that metastasis could be limited by 
platelet depletion; it was subsequently shown that metastasis of many tumor cell 
types (in the experimental setting) was facilitated by platelet interaction with 
tumor cells (78-82). The association between platelet aggregation and 
metastasis was later established (83, 84). Transgenic mouse models have since 
demonstrated that reduced platelet counts and function correlate with decreased 
metastasis formation (78, 82, 85, 86). 
The conventional view of the role of platelets in metastasis initially focused 
on the promotion of adhesion and the formation of a protective barrier around 
tumor cells. Platelet barriers have been shown to protect tumor cells from natural 
killer cells (87, 88). Platelets also have been shown to protect tumor cells from 
shear stress and promote endothelial adhesion (89-94). It was subsequently 
 25 
 
hypothesized that platelet-tumor emboli cause ischemic damage to the 
endothelium, facilitating binding and arrest of platelet-tumor aggregates, but 
while this hypothesis has intuitive appeal, experimental evidence supporting this 
view is lacking (87, 88).  
Tumor emboli are well-known to include aggregated platelets (95, 96). 
Correlations have been experimentally identified between the ability of tumor 
cells to induce platelet aggregation in vitro and the degree to which platelets 
facilitate metastasis for those tumor cell types in vivo (79, 81). Circulating tumor 
cells appear to have the capacity to facilitate platelet activation and promote 
platelet aggregation (97). It is now established that platelets interact directly with 
tumor cells, improving the ability of tumor cells to survive in circulation (95, 96).  
Early attempts to translate this work into therapy focused on the question 
of platelet aggregation and the platelet-tumor embolus. Initial attempts to block 
experimental tumor metastasis with aspirin and ticlodipine were largely 
unsuccessful (83, 93, 98-100). In contrast, partial diminution of in vivo pulmonary 
metastasis was demonstrated using an anti-von Willebrand factor antibody and 
an anti-GP2b-3a antibody, supporting the role for platelets in metastasis via 
systems reliant on integrin GP2b-3a, P-selectin, fibronectin, fibrin, von Willebrand 
factor, and thrombin (93). There is further experimental support for involvement 
of laminin, vitronectin, type IV collagen, thrombospondin, and several integrin 
receptors (alpha3-beta1, alpha5-beta1, and alpha5-beta-3) in platelet-tumor 
interactions (101-108). 
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Recalling that tumors co-opt systems with normal functions, it should be 
recognized that some of the mechanisms through which platelets impact tumor 
biology are dysregulated mechanisms by which platelets otherwise would 
participate in healthy wound repair. Abnormal tumor vasculature functions poorly, 
reflected by chaotic, stagnant, even reversed flow (109, 110). The resulting 
hypoxic, acidic microenvironment is associated with protease-mediated matrix 
remodeling, anchorage-independent growth, and resistance to apoptosis (111, 
112). It is intuitive that this environment also should permit increased platelet 
extravasation followed by a cascade of increased platelet activation, and a feed-
forward loop should be anticipated, especially given that platelets are already 
known to increase adhesion to VEGF-activated endothelial cells (113). The 
impact of platelets on systemic, serum levels of angiogenic mediators is an area 
of on-going study (114). Platelets have elevated angiogpoietin-1 in cancer 
patients and sequester significant VEGF (115, 116). It has been hypothesized 
that platelets may nudge the balance of angiogenic regulators toward a net pro-
angiogenic balance in cancer patients (117). Recent evidence has supported 
platelet sequestration and differential release of angiogenic mediators in the face 
of differential environmental stimuli, and prominent researchers have advocated 
this phenomenon as a possible screening mechanism for the early detection of 
solid malignancy (118-120). Recent evidence suggests that platelet release of 
alpha-granule contents is variable based on pH and that at relatively low pH, 
platelet-driven neutrophil chemotaxis becomes prominent (121). 
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Platelet provision of mitogenic signaling to cancer cells remains under-
studied. Purinergic signaling from platelets has been shown to influence cell 
migration and proliferation (122). Dense granules release agents known to 
modulate cell growth and migration (123, 124). Alpha granules have emerged as 
mediators of pro- and anti-angiogenic effector molecules (118, 125, 126). Many 
of these proteins have mitogenic significance. For example, VEGF and PDGF 
signaling are known to be pro-proliferative, pro-migratory, and anti-apoptotic. A 
cancer with the capacity to co-opt to that system of platelet-driven angiogenesis 
regulation would be able to promote its own angiogenesis and impart upon itself 
a significant survival advantage, potentially decreasing responsiveness to 
traditional cytotoxic agents.  In solid malignancy, soluble growth factors and 
cytokines secreted by stromal cells have been shown to contribute to the so-
called epithelial-to-mesenchymal transition, a reversible alteration of phenotype 
in which increased motility and invasive capacity is seen (127, 128). TGF-beta is 
known to promote the epithelial-to-mesenchymal transition and invasive capacity 
of solid malignancies (129). Platelet-derived TGF-beta signaling through the 
Smad and NF-kB pathways via direct platelet interaction with tumor cells 
facilitated metastasis from a subcutaneous in vivo model to the lung (130). 
 
Drugs and Platelet Function 
Platelets clearly warrant attention as targetable mediators of 
angiogenesis. Aspirin is a commonly used inhibitor of platelet aggregation, acting 
via irreversible acetylation of components of cyclooxygenase (COX)-1 and COX-
 28 
 
2. COX-1 is widely expressed in platelets, and blockade COX-1 function results 
in failed prostaglandin synthesis and therefore failed Thromboxane A2 synthesis, 
thus blocking thromboxane-dependent platelet activation and aggregation (131-
134). Aspirin is a relatively weak inhibitor of platelet activation and aggregation 
because multiple other activating stimuli, (e.g. shear force, catecholamines, 
thrombin, and ADP) are capable of activating platelets in the face of 
aspirinization through non-thromboxane-dependent mechanisms (135). Recent 
interest has emerged regarding aspirin as a chemopreventative agent. A series 
of meta-analyses of secondary end-points of randomized and case-control 
studies have indicated a significant hazard benefit with respect the to the 
development of multiple malignancies in people allocated to even low-dose 
aspirin use (136-139). These investigations, while thought-provoking, should be 
interpreted with care in view of their retrospective (and therefore necessarily 
biased) point of view and reliance on secondary end-points. 
ADP is a biologically significant platelet activator. Platelets have at least 
two distinct receptors that interact with ADP, the P2Y1 and P2Y12 receptors (140). 
ADP signaling through these receptors is responsible for ADP-driven platelet 
activation. P2Y12 is the more platelet-selective of the two receptors in its 
expression, and it is currently targeted in clinic by ticlodipine and clopidogrel. No 
P2Y1 selective antagonists are currently used in the clinical setting. It is notable 
that while ADP is itself a relatively weak platelet activator, the amplification of 
platelet aggregation caused by release of ADP from dense granules is an 
important part of platelet aggregation; blockade of this of this activation-
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amplification-effect by P2Y12 antagonists secondarily tamps down the platelet 
activation effects of other platelet agonists such as thromboxane A2, collagen, 
and thrombin (141, 142). 
The final, common pathway for platelet activation involves integrin-driven 
signaling via the interaction of either fibrinogen or von Willebrand factor with 
integrin alpha-2b-beta-3 on the platelet surface (143-145). The success of aspirin 
and P2Y12 inhibitors at improving cardiovascular mortality led to exploration of 
inhibitors of this pathway in the hope of achieving an improved means of clinical 
inhibition of platelet aggregation. Clinically available agents have been developed 
but remain outside the scope of common use as they did not offer significant 
clinical benefits over existing agents. In breast cancer, the GP2b-3a inhibitor 
eptifibatide was found to suppress metastasis (146). 
Multiple alternative and experimental agents exist in the cardiovascular 
literatures that are outside the scope of the current discussion. However, within 
the context of integrin signaling, the cardiology literature has recently suggested 
the importance of focal adhesion kinase as a component of platelet function. In 
particular, where conventional wisdom had held that platelets tend to remain 
static, recent evidence suggests that platelets will migrate in response to shear 
stress, that migration is associated with redistribution of focal adhesion kinase, 
and that platelets from a mouse that is megakaryocyte-null for focal adhesion 
kinase have limited capacity to migrate in response to fibrinogen (147, 148). The 
use of a novel focal adhesion kinase-inhibitor on platelets decreased reactivity in 
a manner partially reversed by the addition of ADP and also caused defective 
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transition from filodipodia to lamellopodia (149). It is well-known that focal 
adhesion kinase over-expression is associated with adverse outcomes in solid 
malignancy, however the implications of findings in platelets have not been 
evaluated in the context of malignancy (150). 
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Hypotheses and Specific Aims 
 Given the extensive amount of work done to elucidate the normal platelet 
function and the participation of platelets in the regulation and management of 
normal wound healing and angiogenesis, and given the large volume of work 
currently being done on the subject of the therapeutic management of 
angiogenesis as it relates to the treatment of cancer, it remains that there is 
insubstantial literature on the relationship of platelets to tumor angiogenesis and 
aggressive biological behavior. Further, given the long-held relationship between 
platelets and tumor cell metastasis, very little work has been done to explain the 
relationship between platelets and metastasis.  
Therefore, the unified hypothesis for this work is that platelets are a key 
component of the tumor microenvironment whose normal functions as 
angiogenic regulators are co-opted to promote the well-being, selection, 
promotion, and metastasis of cancer, thereby contributing to the phenomenon of 
resistance to anti-angiogenic therapy. This central hypothesis can be divided into 
four sub-hypotheses, with specific aims embedded, as follows: 
- Hypothesis 1. Platelet levels can be used as a biomarker of prognosis and 
recurrence in ovarian cancer. 
o Specific Aim 1. Determine the clinical implications of elevated 
platelet counts at the time of cancer diagnosis, during induction 
therapy, in the post-therapy monitoring interval, and at the time of 
recurrence. 
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- Hypothesis 2. Platelets promote apoptosis resistance, proliferation, and 
migration of tumor cells in vitro, and platelets promote chemotherapeutic 
resistance in vivo. 
o Specific Aim 2a. Determine the biological effects in vitro of platelets 
on cancer cells, including effects on proliferation, migration, and 
apoptosis. 
o Specific Aim 2b. Determine the biological effects of platelet 
depletion and platelet transfusion in vivo. 
- Hypothesis 3. Platelet mitogenicity is driven by platelet activation and 
subsequent signaling at least in part by the platelet-derived growth factor 
and transforming growth factor beta pathways. 
o Specific Aim 3a.  Determine the relevant signaling pathways 
responsible for the observed biology in vitro. 
o Specific Aim 3b. Determine whether platelet activation is necessary 
for the observed biology in vitro. 
o Specific Aim 3c. Determine whether any component of apoptosis 
resistance may be reasonably explained by platelet uptake of 
taxanes. 
o Specific Aim 3d. Determine whether blockade of platelet activation 
in vivo abrogates the observed effects of platelet transfusion on 
tumor growth. 
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- Hypothesis 4. Platelet promotion of tumor cell apoptosis resistance, 
proliferation, and migration in vivo represents a mechanism of resistance 
to anti-angiogenic therapy. 
o Specific Aim 4a. Model resistance to anti-angiogenic therapy in an 
orthotopic model of ovarian cancer. 
o Specific Aim 4b. Determine whether the use of agents known to 
block platelet migration and/or activation can be used to abrogate 
the biological effects of platelet interaction with cancer. 
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Methods 
Approvals 
 Approval for relevant studies was obtained from the University of Texas at 
M.D. Anderson Cancer Center Institutional Review Board (IRB). All animal 
experiments were approved and supervised by the MDACC Institutional Animal 
Care and Use Committee. Approval for clinical studies at collaborating 
institutions (University of Iowa, University of Maryland, and the University of 
Virginia) was obtained from the relevant review boards at those institutions. 
 
Statistical Considerations 
For mouse-driven experiments, sample size was estimated utilizing a two-way 
ANOVA model.  For an effect size of 0.65, a sample size of 10 mice per group 
was considered sufficient to provide 80% power for a test utilizing a significance 
level of 0.05. A 2-sided long-rank statistic was used to compare Kaplan-Meier 
survival curves that were created within the computer program SPSS (IBM®, 
Armonk, New York). Variables estimated to have a normal distribution were 
compared using the Student’s T-Test using Excel (Microsoft®, Redmond, 
Washington). The F-Test was used to compare variances where indicated. A p-
value of <0.05 was considered statistically significant.   
 
Clinical Analysis 
 After IRB approval was obtained, patients were identified at the University 
of Texas at M.D. Anderson Cancer Center (MDACC), the University of Iowa, the 
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University of Maryland, and the University of Virginia who were diagnosed with 
ovarian, primary peritoneal, or fallopian tube carcinoma.  Patients were excluded 
if they did not receive primary therapy at the institution of record or did not have 
routine follow-up at that institution.  Patients were further excluded for a history of 
other malignancy, myeloproliferative disease, inflammatory disease, 
splenectomy, or other confounding cause of thrombocytosis prior to their 
diagnosis of cancer. Patients were excluded if they did not have recurrence of 
disease.  All patients were treated by surgical cytoreduction performed by a 
gynecologic oncologist in addition to adjuvant or neoadjuvant taxane- and/or 
platinum-based chemotherapy. Surgical staging was performed according to 
International Federation of Gynecology and Obstetrics guidelines. All treatments 
were administered at the institution of record. Specimens were reviewed by a 
gynecological pathologist at the institution of record. Clinical data collected 
included patient demographics, tumor characteristics, details of treatment, as 
well as outcomes data such as progression-free interval and overall survival. 
Optimal cytoreduction was defined by convention as residual disease less than 1 
cm as reported by the surgeon of record. Platelet levels and CA-125 
measurements were recorded at the time of primary evaluation, through therapy, 
after the completion of surgery and 6 cycles of cytotoxic chemotherapy, during 
the post-therapy monitoring period, and at the time of diagnosis of ovarian cancer 
recurrence. Thrombocytosis was defined as a platelet count greater than 
450,000/mL (151). Patients who were known to be alive and/or progression-free 
at the time of last contact were censored accordingly. 
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Cell lines and culture conditions 
      The derivation of the human ovarian cancer cell lines 2774, A2780, HeyA8, 
SKOV3-IP1, and 2774 are previously reported (152-156). The cell line 2774 was 
maintained in MEM media supplemented with 5% fetal bovine serum (FBS), 1x 
L-glutamine, 1x sodium pyruvate (100mM stock, Invitrogen, Carlsbad, CA), and 
1x non-essential amino acid.  The cell lines A2780, HeyA8, and SKOV3-IP1 were 
maintained in RPMI-1640 medium with 15% FBS. HeyA8-MDR and SKOV3-TR 
are taxane-resistant derivations of HeyA8 and SKOV3ip1 (Dr. Isaiah J. Fidler, 
MDACC, Houston, TX).  The taxane-resistant phenotype was maintained by 
adding 300 ng/mL (HeyA8-MDR) and 100 ng/mL (SKOV3-TR) of paclitaxel to the 
media used for HeyA8 and SKOV3-ip1 (above). The MDA-MB-231 metastatic 
human breast cancer cell line was established from pleural effusions (Dr. Janet 
Price, MDACC, Houston, TX) (157). MDA-MB-231 cells were maintained in 
RPMI-1640 media with 5% FBS. The cell line OVCAR5 was developed from 
human serous ovarian carcinoma (158). OVCAR5 cells were maintained in 
DMEM media with 10% FBS. The cell line RMUG-S was established from human 
mucinous ovarian carcinoma (159). RMUG-S cells were maintained in RPMI-
1640 media with 10% FBS. The syngeneic mouse ovarian cancer cell line ID8 
was developed from the surface epithelium of C57B6 mice (160). ID8 cells were 
maintained in DMEM media with 5% FBS and 1x Insulin-Transferrin-Sodium 
Selenite. 50-70% cell confluence was considered appropriate for in vitro 
experiments. Cell lines were routinely genotyped to confirm identity. Cell lines 
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were also routinely tested to confirm absence of Mycoplasma.  Cells were 
maintained at 37°C in a humidified incubator infused with 20% O2 and 5% CO2, 
referred to as the normoxic condition. For hypoxia-based experiments, cells were 
placed in a hypoxia chamber (Bellow Glass, Inc., Vineland, NJ) infused with 0% 
O2, 5%CO2, and 95% N2 also at 37oC. 
 
Orthotopic model of ovarian cancer in nude mice 
Female athymic nude (NCr-nu) were purchased from Taconic Farms, Inc. 
(Rockville, MD). The development and characterization of the orthotopic mouse 
model of ovarian cancer has been previously described (161-163). Briefly, 
SKOV3-IP1 (1 x 106), A2780 (1 x 106), HeyA8 (0.25 x 106), or 2774 (2 x 106) 
human ovarian cancer cells lifted with trypsin/edta, washed with PBS, and 
resuspended in 200 mL of Hank’s balanced salt solution (HBSS, Mediatech, Inc. 
Manassas, VA) and were injected into the peritoneal cavity of female nude mice.  
All cell lines have been shown to reliably form macroscopic tumor implants on 
peritoneal surfaces throughout the pelvis and abdominal cavity. 
 
Platelet isolation for in vitro assays 
 Platelets were prepared for in vitro assays in a manner that would remove 
plasma contents and nucleated cells. Whole blood was drawn from the inferior 
vena cava of anesthetized nude mice into a syringe pre-loaded with 1:9 v/v 3.8% 
sodium citrate and then mixed 1:1 v/v with tyrodes buffer (140 mM NaCl, 2.7 mM 
KCl, 12 mM NaHCO3, 6.45 mM NaH2PO4, 5.5 mM glucose in diH20) lacking Mg2+ 
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and Ca2+. Blood was centrifuged at 1100 rpm for 3 minutes, twice, at room 
temperature in order to separate platelet-rich plasma from red blood cells and 
leukocytes by room temperature centrifugation of blood at 1100 rpm for 3 
minutes, performed twice. In order to separate larger cells and proteins, the 
platelet-rich plasma was then passed through a filtration column using 
Sepharose 2B beads (Sigma Aldrich, St Louis, MO) loaded into a siliconized 
glass column also containing a 10 mcm nylon net filter (Millipore, Billerica, MA). 
Prior to being placed in the column, Sepharose 2B beads were washed in 
acetone 1:1 v/v, followed by 0.9% NaCl 1:1 v/v, and “Buffer 1” 1:1 v/v (134 mM 
NaCl, 12 mM NaHCO3, 2.9 mM KCl, 0.34 mM Na2HPO4, 1 mM MgCl2, 10 mM 
Hepes, 5 mM glucose, 0.3g/100 mL bovine serum antigen, pH 7.4). After the 
beads were loaded onto the column with the filter, the were again washed with 
“Buffer 1.”  Platelet-rich plasma was loaded onto the column and allowed to enter 
the beads fully before additional buffer was added. The initial, clear eluent was 
discarded. Cloudy eluent was collected. Eluent was diluted 1:200 and platelets 
were counted with a hemocytometer by phase-contrast microscopy at 400x 
magnification.  
 
In vitro apoptosis 
 To assess the effect of platelets on apoptosis, cells were plated in 6-well 
plates at 50,000 cells per plate, targeting approximately 50% confluence in 
serum-containing medium. After adequate starting confluence was confirmed, 
media was changed to serum-free for approximately 24-hours prior to the start of 
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treatment. After serum-starvation, platelets were isolated (as described above), 
and platelets were added to achieve a final dose of 1 x 108 platelets/mL.  
Docetaxel was used at previously published IC50 dose to induce apoptosis. 
Controls were established using an equivalent volume of the appropriate buffer. 
All treatments were performed in triplicate. In the case of transfection as 
treatment, double transfection was performed as described below. After 72 hours 
of platelet and docetaxel exposure, cell viability was assessed using Annexin V 
and 7-amino-actinomycin-D (7AAD) staining (BD PharmingenTM, Franklin Lakes, 
NJ) by flow cytometry. Briefly, cells were harvested, washed in PBS, and 
incubated with PE-Annexin V and 7AAD according to package insert instructions 
for 20 minutes prior to flow cytometric analysis. Indirect mediation of effect was 
considered by the use of an intervening cell culture insert with 0.4 mcm pores 
(BD FalconTM, Franklin Lakes, NJ) in which platelets and/or docetaxel and/or 
control buffer was placed during co-incubation experiments. 
 
In vitro proliferation 
To assess the effect of platelets on proliferation, cells were plated in 6-well 
plates at 50,000 cells per plate, targeting approximately 50% confluence in 
serum-containing medium. After adequate starting confluence was confirmed, 
media was changed to serum-free for approximately 24-hours prior to the start of 
treatment. After serum-starvation, platelets were isolated (as described above), 
and platelets were added to achieve a final dose of 1 x 108 platelets/mL. An 
equivalent volume of buffer was used for control, and all treatment groups were 
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performed in triplicate. In the case of transfection as a treatment, reverse 
transfection was performed as described below and other treatment (e.g. platelet 
co-culture) was started 48 hours after transfection. After 24 hours of treatment, 
the percentages of cells proliferating (defined as S-phase) were determined 
using the Click-iT EdU flow cytometry kit (Invitrogen, Carlsbad, CA). Cells were 
incubated with 10 mcM 5-ethynyl-2-deoxyuridine (EdU) for 2 hours, lifted, and 
washed with 1% bovine serum antigen in d-PBS. Cells were fixed with 4% 
paraformaldehyde in d-PBS for 15 minutes at room temperature and then 
maintained at 4oC protected from light until the time of flow cytometric analysis, a 
duration not to exceed 7 days. On the day of analysis, cells were washed in 1% 
BSA in d-PBS and then permeabilized with 1x saponin-based reagent for 15 
minutes at room temperature. The cells were then incubated with a solution of 1x 
reaction buffer, CuSO4, Alexa-Fluor 488 azide dye, and proprietary reaction 
buffer additive for 30 minutes at room temperature prior to flow cytometric 
analysis. 
 
In vitro migration 
 To assess the effect of platelets on cancer cell migration, a modified 
Boyden chamber system was used. The wells separated by a 0.1% gelatin-
coated, cell-permeable membrane. Platelets were isolated as described above 
and added to serum free media to a final concentration of 1 x 108 cell/mL, and 
this platelet solution was added to the bottom wells. An equivalent volume of 
buffer was used as the control. Cancer cells were added to the top wells at 
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approximately 100,000 cells/well. Incubation was at 37oC for 6 hours. After 
incubation, cells in the bottom chambers were removed using 0.1% EDTA and 
were loaded onto a 3 mcm polycarbonate filter (Osmonics, Livermore, CA) with 
the S&S Minifold I Dot-Blot System (Schleicher & Schuell, Keene, NH). Cells 
were stained and scored by counting cells from five representative 100x fields.  
 
ADP quantification 
 To assess the relative production of ADP in hypoxic compared to 
normoxic environments, cancer cells were cultured in serum free medium in 
hypoxic compared to normoxic environments, and the ADP content of 
conditioned medium was assessed at various time-points using the ABCAM 
(Cambridge, England) ADP colorimetric assay kit. The assay was performed 
according to the manufacturer protocol. 
 
Forward transfection 
 As a means of investigating the cause of the biological endpoints of 
proliferation and apoptosis (described above) transfection of small-interfering 
RNA (siRNA) was performed. In the case of forward transfection, 6-well plates 
were inoculated with 50,000 cancer cells per well with a goal of transfection at 
50% confluence within 12-24 hours of plating. Based on validation experiments, 
the appropriate amount of the siRNA of choice was incubated for 20 minutes at 
room temperature in serum-free culture medium (1 mL/well) with Lipofectamine 
2000 (Invitrogen, Carlsbad, CA) at a 3.75:1 ratio of volume Lipofectamine 2000 
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to microgram siRNA. After incubation, cell culture media was removed from the 
6-well plates and replaced with the siRNA/Lipofectamine-containing medium at 1 
mL per well. Cells and transfection media were incubated at 37oC for 4 hours, 
and then transfection medium was changed to serum-containing medium. 
Treatment experiments were started 48 hours after transfection. If forward 
transfection was performed as the second step of a “double” transfection 
(described below) then treatment experiments were started immediately in 
serum-free media. 
 
Reverse transfection 
 As a means of investigating the cause of the biological endpoints of 
proliferation and apoptosis (described above) transfection of siRNA were 
performed. In the case of reverse transfection, and based on previously 
performed validation experiments, the appropriate amount of the siRNA of choice 
was incubated for 20 minutes at room temperature in serum-free culture medium 
(200 mcL/well) with Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA) at a 3:1 
ratio of volume of Lipofectamine RNAiMAX to mcL siRNA. After incubation, 200 
mcL of the solution was placed in each well, and then 50,000 cancer cells in 1 
mL of serum-free media were added to each well. Cells were incubated with the 
transfection medium for 4-6 hours at 37oC, and then medium was changed to 
serum-containing medium. Treatment experiments were started 48 hours after 
transfection. 
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Double transfection 
 If a longer duration of mRNA knockdown was needed than was offered by 
single forward or reverse transfection, then sequential double transfection was 
used. In this case, reverse transfection was initially performed, and 48 hours 
later, a forward transfection was performed, and treatment experiments were 
initiated within 1-2 hours of the completion of the forward transfection. 
 
RNA Extraction 
      Total RNA was extracted from cells growing in vitro using RNeasy Kit 
(Quiagen, Venlo, Netherlands). Cells were lifted with trypsin/edta, washed with 
PBS, and centrifuged at 10,000 rpm for 5 minutes to form the pellet. The 
supernatant was discarded, and RNA was extracted according to the company 
protocol. RNA was quantified using a spectrophotometer and 1 mcg was 
transcribed into complementary DNA (cDNA) using the Verso cDNA kit (Thermo 
Fisher Scientific), closely following the manufacturer’s protocol.  Quantitative RT 
PCR was then used to assess levels of expression.                           
 
CD31 immunohistochemistry 
 In order to assess the vasculature in tumor tissue harvested from 
orthotopic models of ovarian cancer, immunohistochemistry was performed for 
CD31. The primary antibody was a rat anti-mouse antibody to CD31 
manufactured by BD Pharmingen (Franklin Lakes, NJ), catalogue number 53370. 
The secondary antibody was goat anti-rat HRP manufactured by Jackson 
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ImmunoResearch (West Grove, PA), catalogue number 112-035-167. Frozen 
tumor sections were fixed in acetone, followed by acetone/chloroform, followed 
by acetone. Endogenous peroxides were blocked with 3% hydrogen peroxide in 
methanol, and non-specific proteins were blocked with 5% normal horse serum 
and 1% normal goat serum in PBS. Slides were incubated over-night in primary 
antibody at 1:800 dilutions in the same protein block. After washing with PBS and 
protein blocking, the sections were incubated in the secondary antibody at 1:200 
in protein block. Slides were developed with DAB chromogen (Invitrogen, 
Carlsbad, CA) and counterstained with Gil No.3 hematoxylin (Sigma-Aldrich, St. 
Louis, MO).   
 
Cleaved caspase 3 immunohistochemistry 
 In order to assess apoptosis rates in tumor tissue harvested from 
orthotopic models of ovarian cancer, immunohistochemistry was performed for 
cleaved caspase 3. The primary antibody was a rabbit polyclonal anti-human 
antibody to cleaved caspase 3 manufactured by BioCare Medical (Concord, CA), 
catalogue number CP229B. The secondary antibody was goat anti-rabbit 
biotinylated from BioCare Medical, catalogue number 111-036-047, and 
streptavidin HRP 4+ from BioCare Medical, catalogue number HP604H. Paraffin 
embedded tumor sections were heated to 60oC for 45 minutes and were 
deparaffinized sequentially in xylenes and declining grades of ethanol prior to 
rehydration.  Antigen retrieval was performed by steaming slides at 100ºC for 30 
minutes in BioCare Medical borg-decloaker, Ready-to-Use. Endogenous 
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peroxides were blocked with 3% hydrogen peroxide in methanol, and non-
specific proteins were blocked with 4% fish gelatin in PBS. Slides were incubated 
over-night in primary antibody (1:100) in the same protein block. After washing 
with PBS and protein blocking, the sections were incubated in the secondary 
antibody (ready-to-use) followed by streptavidin HRP (ready-to-use). Slides were 
developed with DAB chromogen (Invitrogen, Carlsbad, CA) and counterstained 
with Gil No.3 hematoxylin (Sigma-Aldrich, St. Louis, MO).   
 
Ki67 immunohistochemistry 
 In order to assess the proliferation rates in tumor tissue harvested from 
orthotopic models of ovarian cancer, immunohistochemistry was performed for 
Ki67. The primary antibody was a rabbit polyclonal anti-human antibody to Ki67 
manufactured by ThermoFisher Scientific (Houston, TX), catalogue number RB-
90-43-P. The secondary antibody was goat anti-rabbit HRP (Jackson 
ImmunoResearch). Paraffin embedded tumor sections were heated to 60oC for 
45 minutes and were deparaffinized sequentially in xylenes and declining grades 
of ethanol prior to rehydration.  Antigen retrieval was performed by steaming 
slides at 100ºC for 30 minutes in BioCare Medical Civa decloaking solution, 
diluted to 1x in water. Endogenous peroxides were blocked with 3% hydrogen 
peroxide in methanol, and non-specific proteins were blocked with 5% normal 
horse serum and 1% normal goat serum in PBS. Slides were incubated over-
night in primary antibody (1:200) in the same protein block. After washing with 
PBS and protein blocking, the sections were incubated in the secondary antibody 
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(1:500 in protein block). Slides were developed with DAB chromogen (Invitrogen, 
Carlsbad, CA) and counterstained with Gil No.3 hematoxylin (Sigma-Aldrich, St. 
Louis, MO).   
 
Platelet and CD31 co-immunofluorescence 
Using the orthotopic model of ovarian cancer described above, mice were 
inoculated with tumor. At the time of sacrifice, the mouse was anesthetized with 
isofluorane, and intravital fixation was performed with 4% paraformaldehyde 
(described below) and tumor was frozen for future staining. The primary antibody 
was rat anti-mouse IgG to the GP1b-beta subunit of the GP1b-V-IX complex 
primarily labeled with DyLight488 (Emfret Analytics, Eibelstadt, Germany) at 
1:100 dilutions. The second primary antibody was CD31 rat anti-mouse (BD 
Pharmingen, catalogue number 553370) and its secondary was goat anti-rat 
Alexa 594 (1:200) were applied. Frozen sections were fixed in cold acetone for 
10 minutes. After protein block with 5% normal horse serum and 1% normal goat 
serum, the primary anti-GP1b-beta antibody was applied at 1:100 dilution over-
night at 4oC. After PBS wash, protein block was 5% normal rat serum (Jackson 
ImmunoResearch, catalogue number 012-000-120) for 1 hour followed by F(ab’)2 
fragment Goat anti Rat IgG, F(ab’)2 fragment specific (Jackson 
ImmunoResearch, catalogue 112-007-003) diluted 1:50 in protein block, incubate 
for 2 hours. The slides were then incubated at 1:800 dilutions in protein block 
overnight at 4oC. After washing and protein blocking, the secondary was added 
at 1:1000 dilutions and incubated at room temperature for 1 hour. Hoescht 33342 
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(Invitrogen) counterstain was applied at 1:10000 dilution in PBS for 10 minutes, 
and slides were mounted using propyl-gallate (Fisher Scientific, Hampton, NH) 
and glass cover slips. Slides were stored at 4oC in the dark. 
Intravital fixation 
 At the time of animal sacrifice, and after appropriate treatments, the 
relevant mice were anesthetized with isofluorane. An incision was made in the 
chest cavity allowing visualization of the left heart, and a 21-guage needle was 
used to deliver 4% paraformaldehyde in PBS through heart and into the 
ascending aorta. Slow, manual infusion was continued for approximately 5 
minutes, infusing approximately 25 mL, and until all movement of the mouse had 
stopped. The absence of heartbeat or breathing was confirmed. Relevant 
dissection was then undertaken. 
 
Platelet-depleting antibody 
 To deplete platelets in mice for in vivo experiments, use used a 
commercially available rat anti-mouse monoclonal antibody directed against 
mouse GP1b-alpha (CD42b, Emfret Analytics, Eibelstadt, Germany) that causes 
irreversible Fc-independent platelet depletion within 60 minutes of administration 
without inducing platelet activation. This antibody has been previously used and 
validated in our lab, including dose-kinetics. 
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TGF-beta receptor 1 siRNA validation and knockdown 
 Forward transfection was performed (as described above) using 5 mcg of 
siRNA per well, and quantitative RT-PCR was performed using the primer listed 
in Figure 5 compared to 18S control. Western blot was performed (as described 
above) to confirm effect. Double transfection was performed and validated using 
western blot. The validated sequence is listed in Figure 6 along with the validated 
control. 
 
PDGFR-alpha siRNA validation and knockdown 
 Reverse transfection was performed (as described above) using 20 nM 
siRNA per well, and quantitative RT-PCR was performed using the primer listed 
in Table 4 compared to 18S control. Western blot was performed (as described 
above) to confirm effect. Double transfection was performed and validated using 
western blot. The validated sequences are listed in Table 5. 
Sequence Name Sequence 
PDGFR-alpha (F) 5’-TGAAAGCACACGGAGCTATG 
(R) 5’-TCTAGCATGGGGACATACTGTG 
TGF-beta R1 (F) 5’-GATGCTGCTTCTCCAAAGTG 
(R) 5’-ACAAGTCAGGATTGCTGGTG 
18S (Loading Control) (F) 5’-CGCCGCTAGAGGTGAAATC 
(R) 5’-TTGGCAAATGCTTTCGCTC 
Table 4: Primers used in the current work. 
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Sequence Name Sequence 
PDGFR-alpha 
(Sigma Aldrich) 
5’-GAAGACAGTGGCCATTATA-3’ 
TGF-beta R1 
(Sigma Aldrich) 
5’-GAAGACAGUGGCCAUUAUAdTdT-3’ 
Control 
(Sigma Aldrich) 
5'-AAUUCUCCGAACGUGUCACGU-3' 
 
Table 5: siRNA sequences used in the current work. 
 
Aspirinization of platelets 
Pharmacy grade aspirin was acquired, and a single 325 mg table was 
dissolved in 500 mcM sodium acetate (pH 5.6). This was added 1:10 v/v to 
platelet rich plasma and the combination was incubated at 37oC for 15 minutes. 
Incubation with an equivalent sodium acetate solution without aspirin was 
performed as a control. 
 
Small molecule inhibitor of Focal Adhesion Kinase 
 GSK2256098, a novel small molecule inhibitor of Focal Adhesion Kinase 
(FAK) phosphorylation at the tyrosine-397 site, was obtained from 
GlaxoSmithKline (London, United Kingdom) under material transfer agreement. 
Pharmacokinetics and pharmacodynamics have suggested activity in ovarian 
cancer and at the level of the platelet in nude mice at 75 mg/kg given orally by 
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gavage in the carrier 10% 1-methyl-2-pyrrolidinone in polyethylene glycol 300. In 
vitro, kinase inhibition is seen at doses of 0.1 - 1 mcM. (Unpublished data, 
personal communication from Dr. Angela Sanguino, MD Anderson Cancer 
Center.) 
 
Docetaxel 
 Docetaxel (Sanofi-Aventis, Paris, France) was obtained from leftover 
clinical samples through a material transfer agreement with the clinical pharmacy 
associated with the University of Texas M.D. Anderson Cancer Center. Stock 
concentration was 20 mg/mL and was maintained at 4oC. 
 
Platelet protection against induced apoptosis in vitro 
 In order to assess the effect of platelets on induced and spontaneous 
apoptosis, cancer cell lines were plated in 6-well plates as described above. After 
exposure to serum-free conditions for 24 hours, treatment was initiated. Plasma-
free platelets were isolated (as described above) and counted. Cells were co-
cultured, either by direct or indirect exposure, with platelets at 1 x 108 million 
cells/mL, docetaxel dosed to previously documented IC50, or both. Appropriate 
buffer in an equivalent volume was added for control. In order to investigate the 
contribution of TGF-beta receptor 1 and PDGF receptor alpha, double-
transfection was performed, and treatment was initiated after the second 
(forward) transfection. Flow cytometric analysis as described above was 
performed 72 hours after initiation of treatment. 
 51 
 
 
Platelet acceleration of proliferation in vitro 
 In order to assess the effect of platelets on cancer cell proliferation, cancer 
cell lines were plated in 6-well plates as described above. After exposure to 
serum-free conditions for 24 hours, treatment was initiated. Plasma-free platelets 
were isolated (as described above) and counted. Cells were co-cultured with 
platelets at 10 million cells/mL with an appropriate volume of buffer added to the 
control wells. In order to investigate the contribution of TGF-beta receptor 1 and 
PDGF receptor alpha, reverse transfection was performed, and treatment was 
initiated 48 hours after transfection. Flow cytometric analysis as described above 
was performed 24 hours after initiation of treatment. 
 
Blockade of platelet effect by platelet fixation 
 In order to assess whether platelet activation was necessary for the 
observed effects, the apoptosis and proliferation assays described previously 
were repeated including platelets that had been fixed with paraformaldehyde. 
Specifically, after plasma-free platelets were isolated, half were incubated in 1% 
paraformaldehyde in dPBS at room temperature for 15 minutes. Untreated 
platelets were incubated in an equivalent volume of PBS. Platelets were then 
centrifuged at 1800 rpm for 10 minutes and re-suspended in Buffer 1. A parallel 
solution of Buffer 1, paraformaldehyde, and PBS was processed in parallel to use 
as a control for the residual paraformaldehyde left after paraformaldehyde-fixed 
platelets were washed and re-suspended. After 24 hours (proliferation) and 72 
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hours (apoptosis) flow cytometric analysis was performed as previously 
described. 
 
Platelet acceleration of tumor cell migration in vitro 
 In order to assess the effect of platelets on cancer cell migration, cancer 
cells were added to a Boyden chamber system as described above. Plasma free 
platelets were isolated and counted and added to the serum free media at 1 x 
108 cells/mL. An equivalent volume of buffer was used as the control. After 6 
hours of incubation at 37oC, cells were removed and scored as described above. 
 
Biodistribution 
 In order to determine relative docetaxel drug concentrations in human 
plasma and human platelet samples, uptake of drug into platelets with respect to 
other blood fractions was considered using High-Performance Liquid 
Chromatography (HPLC) with UV-spectrum capability (HPLC-UV). Fresh human 
blood from a healthy, adult female volunteer was collected in sodium citrate 
vacuum tubes (BD Pharmaceuticals, Franklin Lakes, NJ) and divided into 50 mL 
aliquots to be used to assess “high” and “low” concentrations. For the “high” 
concentration, docetaxel was added to a final concentration of 5 mcg/mL. For the 
“low” concentration, docetaxel was added to a final concentration of 1 mcg/mL. 
At multiple time-points, fractions were taken to examine concentration of 
docetaxel in the whole plasma (plasma + platelets) compared to platelets 
separated from platelet-free plasma (PFP). Specifically, the whole blood was 
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centrifuged at 1200 rpm for 4 minutes, and 1 mL of plasma was removed. The 
plasma was centrifuged at 7500 rpm for 5 minutes, and the supernatant was 
analyzed as the PFP portion. Pelleted platelets were washed with 1 mL dPBS 
and were centrifuged again at 7500 rpm for 5 minutes. This supernatant was 
discarded and the remaining pellet was suspended in 1 mL of mobile phase for 
immediate HPLC-UV analysis using the column Nova Pak C-18 4µm. 
3.9x150mm with the Nova Pak C-18 4µm Guard Pak. Results were reported in 
ng/mL with a lower limit of quantification of 50 ng/mL. 
 
Thrombocytosis, thrombocytopenia, and effect on chemotherapy in vivo 
 Based on in vitro data obtained, the decision was made to proceed to in 
vivo with the cell lines A2780 and SKOV3-IP1 using an orthotopic model of nude 
mice.  
In the first experiment, animals were inoculated on Day 0 with A2780 cells 
(as described above). On Day 7, treatment was initiated. The first group was 
given twice weekly tail vein injections of Control IgG (0.5 mcg/gram). The second 
group was given twice weekly Control IgG via tail vein injection and weekly 
docetaxel 35 mcg IP. The third group was given the platelet-depleting antibody 
described above at a dose of 0.5 mcg/gram via tail vein injection twice weekly. 
The fourth group was given the platelet-depleting antibody plus docetaxel. Mice 
were treated until they became moribund and were sacrificed at that time. Data 
taken at necropsy included mouse weight, aggregate tumor weight, number of 
tumor nodules, and location of tumor nodules. Tumor was taken for frozen 
storage, frozen section, and paraffin block. 
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In the second experiment, animals were inoculated on Day 0 with SKOV3-
IP1 (as described above). On Day 7, treatment was initiated. The first group was 
given Control IgG. The second group was given platelet-depleting antibody. The 
third group was given tail vein transfusion of platelet rich plasma isolated from 
nude mice as described above. The fourth group was given Control IgG and 
docetaxel. The fifth group was given platelet-depleting antibody and docetaxel. 
The sixth group was given platelet transfusion and docetaxel. Mice were treated 
until they became moribund and were sacrificed at that time. Data taken at 
necropsy included mouse weight, aggregate tumor weight, number of tumor 
nodules, and location of tumor nodules. Tumor was taken for frozen storage, 
frozen section, and paraffin block. 
 
Effect of aspirin on tumor cell proliferation in vitro 
 Based on the hypothesis that platelet effects on tumor may be due to 
platelet activation, and based on the knowledge that aspirin is a weak inhibitor of 
platelets, we dissolved a 325 mg tablet of aspirin in deionized, distilled water, 
filter sterilized it. Cancer cells were plated in 6-well plates as described above 
and exposed to serum-free conditions for 24 hours. Plasma-free platelets were 
isolated as above and half of the platelets were co-incubated with 30 mcM aspirin 
for 15 minutes. Platelets were counted. A control group was given an appropriate 
volume of buffer. An additional control group was given an equivalent 
concentration of aspirin. A group was treated with non-aspirin-exposed platelets 
at 1 x 108 cells/mL, and the final group was treated with the same number of 
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aspirinized platelets. After 24 hours of treatment, flow cytometric analyses for 
proliferation (as described above) was performed. 
 
Effect of aspirin on thrombocytosis and malignancy in vivo 
Based on accumulated in vitro and in vivo data, the hypothesis was 
formed that aspirinization of platelets would at least partially block platelet 
activation and therefore would at least partially abrogate the effects of platelet 
transfusion on progression of malignancy in our orthotopic mouse model of 
ovarian cancer. In this experiment, animals were inoculated on Day 0 with A2780 
cells (as described above). On Day 7, treatment was initiated. The first group 
served as an untreated control. The second group was given intraperitoneal 
aspirin 20 mg/kg twice per week. The third group was given 500 mcL of platelet 
rich plasma isolated from nude mice and incubated with sodium acetate for 15 
minutes (as described above) via tail vein injection weekly. The fourth group was 
given weekly tail vein transfusion of platelet rich plasma that had been incubated 
for 15 minutes with a 50 mcM solution of aspirin in sodium acetate (as described 
above). Mice were treated until they became moribund and were sacrificed at 
that time. Data taken at necropsy included mouse weight, aggregate tumor 
weight, number of tumor nodules, and location of tumor nodules. Tumor was 
taken for frozen storage, frozen section, and paraffin block. 
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Effect of the FAK inhibitor on proliferation in vitro 
 Based on the hypothesis that platelet effects on tumor may be due to 
platelet activation, and based on the knowledge that FAK participates in integrin 
signaling necessary for platelet activation, and based on reports that the absence 
of FAK leads to impaired migration and activity in platelets, we utilized the 
inhibitor described above to try to block any pro-proliferation effects of platelets. 
Cancer cells were plated in 6-well plates as described above and exposed to 
serum-free conditions for 24 hours. Plasma-free platelets were isolated as above 
and half of the platelets were co-incubated for 15 minutes with an adequate 
concentration of the inhibitor to yield 1 mcM inhibitor in the final incubation. 
Platelets were counted. A control group was given an appropriate volume of 
buffer. An additional control group was given an equivalent concentration of the 
inhibitor. A group was treated with non-inhibitor-exposed platelets at 1 x 108 
cells/mL, and the final group was treated with the same number of inhibitor-
exposed platelets. After 24 hours of treatment, flow cytometric analyses for 
proliferation (as described above) was performed. 
 
Platelet infiltration of solid tumor 
 In order to elucidate whether platelets interact with tumor cells in a 
biological environment, we utilized our orthotopic model of ovarian cancer in 
nude mice. Mice were inoculated with 2774 (as described above). When tumor 
was palpable, the mice were sacrificed via intra-vital fixation. Tumor was 
harvested. Immunofluorescence was performed for the anti-GP42b antibody and 
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for anti-mouse-CD31 to assess for platelet infiltration into the tumor and for 
proximity of platelet infiltration to tumor blood vessels. 
 For comparison, non-tumor bearing mice were injected with 0.5 mL of 3% 
thioglycollate (PD Pharmingen, Franklin Lakes, NJ) by intraperitoneal injection or 
PBS by intraperitoneal injection. After 72 hours, these animals were sacrificed by 
intravital fixation, and peritoneal tissue was harvested and evaluated in the same 
fashion using the anti-GP42b antibody and anti-mouse-CD31 antibody. 
 
Rebound tumor growth after short-term anti-angiogenic therapy 
 Based on pre-clinical and clinical evidence of tumor rebound after the 
withdrawal of anti-angiogenic therapy, we sought to develop a pre-clinical model 
of the phenomenon in our orthotopic model of ovarian cancer in nude mice in 
order to investigate the phenomenon. Animals were inoculated on Day 0 with 
SKOV3-IP1 cells (as described above). In the first group, animals were treated 
with pazopanib 100mg/kg daily for the week prior to inoculation with ovarian 
cancer. In the second group, mice were treated with pazopanib starting 7 days 
after inoculation, and treatment was stopped after 1 week. In the third group, 
mice were treated with pazopanib starting on Day 7 and were treated until the 
conclusion of the experiment. In the fourth group, mice were treated with the 
vehicle carrier for the pazopanib for the seven days prior to cell line inoculation. 
In the fifth group, mice were treated with the vehicle carrier for pazopanib starting 
on day 7 and continuing for the duration of the experiment. The experiment was 
ended when the mice became moribund, and they were sacrificed at that time. 
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Data taken at necropsy included mouse weight, aggregate tumor weight, number 
of tumor nodules, and location of tumor nodules. Tumor was taken for frozen 
storage, frozen section, and paraffin block. 
 
Blockade of rebound tumor growth after short term anti-angiogenic therapy using 
FAK-inhibitor 
 Based on available in vitro data, it was hypothesized that bevacizumab 
would have similar effects to pazopanib when given for a brief interval of time. It 
was further hypothesized that the effects in question could be blocked by treating 
mice with an inhibitor of focal adhesion kinase, given its known effects on platelet 
activation and migration in response to fibronectin. Therefore, a series of in vivo 
experiments were undertaken utilizing our orthotopic model of ovarian cancer. 
 In the first experiment, nude mice were inoculated with SKOV3-1P1 on 
Day 0, and treatment was initiated on Day 7. The first group was an untreated 
control. The second group was treated daily with pazopanib 100 mg/kg by oral 
gavage from Day 7 until the end of the experiment. The third group was treated 
with pazopanib 100 mg/kg by oral gavage from Days 7 – 14 of the experiment. 
The fourth group was treated with pazopanib 100 mg/kg by oral gavage from 
Days 7 – 14 of the experiment, followed by the FAK-inhibitor GSK2256098 75 
mg/kg daily by oral gavage until the end of the experiment. Groups 5 – 7 
recapitulated Groups 2 – 4, except that bevacizumab 6.25 mg/kg IP twice weekly 
was substituted for pazopanib. The experiment was ended when the mice 
became moribund, and they were sacrificed at that time. Data taken at necropsy 
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included mouse weight, aggregate tumor weight, number of tumor nodules, and 
location of tumor nodules. Tumor was taken for frozen storage, frozen section, 
and paraffin block. 
 In the second experiment, nude mice were inoculated on Day 0 with 
HeyA8. The remainder of the experiment recapitulated the first in terms of drug 
dose and schedule. The experiment was ended when the mice became 
moribund, and they were sacrificed at that time. Data taken at necropsy included 
mouse weight, aggregate tumor weight, number of tumor nodules, and location of 
tumor nodules. Tumor was taken for frozen storage, frozen section, and paraffin 
block. 
 A third experiment was undertaken to address the interval of time between 
the short-term treatment with pazopanib and bevacizumab in groups 3 and 6 and 
the end of the experiment and to capture data regarding events in that interval. 
Nude mice were inoculated with SKOV3-IP1 on Day 0 and treatment was 
initiated group-by-group when tumor was palpable. The first group served as an 
untreated control. The second was given pazopanib 100 mg/kg daily by oral 
gavage for 7 days. The third was given bevacizumab 6.25 mg/kg IP every 4 days 
for two doses. The fourth was given the FAK-inhibitor GSK2256098 75 mg/kg by 
oral gavage daily for 7 days. The fifth was given aspirin 20 mg/kg every four 
doses for two doses. Mouse CBC was drawn immediately prior to treatment and 
after 1 week of treatment via retro-orbital collection. After 1 week of treatment, 
blood was also drawn for cytokine measurement, Alexa488-conjugated anti-
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platelet antibody was given, and the mouse was sacrificed by intra-vital fixation. 
Tumor was taken for frozen storage, frozen section, and paraffin block. 
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Results 
Platelets as a biomarker of disease recurrence 
 Patients were identified at the four participating institutions that received 
their diagnosis of epithelial ovarian cancer, their initial surgery and 
chemotherapy, and their post-therapy monitoring within that system. Patients 
were excluded if no recurrence was identified. In this population, enriched for 
recurrence, 341 patients were identified who met criteria for inclusion in this 
analysis. Demographic information is included in Table 4. Briefly, the majority of 
patients had high-stage, high-grade serious epithelial ovarian cancer. 32% met 
formal criteria for thrombocytosis at diagnosis (i.e. >450,000/mcL). Overall, the 
mean platelet level was 409,000/mcL (range 134,000-1,122,000/mcL). The mean 
platelet level for the cohort with thrombocytosis was 554,000/mcL and the mean 
for the cohort without thrombocytosis was 330,000/mcL. 
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Table 6: Patient clinical characteristics.  
 
Patients were typical of an ovarian cancer population with a median age 
61 years. Disease was most commonly high-grade, high-stage serous cancer. 
 Survival analysis of this cohort (Figure 2) was performed to query whether 
elevated platelet levels at the time of diagnosis (greater than 450,000 cells per 
mcL) would be associated with adverse clinical outcomes. Our findings were 
consistent with previous finings that thrombocytosis at diagnosis was associated 
with significantly worse overall survival (median 480 days vs. 625 days, p = 
0.007) and progression free interval (median 386 days vs. 440 days, p = 0.05). 
Patient Clinical Characteristics  
Average  
- Median 
- Range 
- Standard Deviation 
 
61 years 
31-88 years 
11 years 
Stage 
- Low (I, II) 
- High (III, IV) 
- Unknown 
 
29 (8.5%) 
311 (91.2%) 
1 (0.29%) 
Grade 
- Low 
- High 
 
38 (11.1%) 
303 (88.9%) 
Histology 
- Serous 
- Other 
 
269 (78.8%) 
72 (21.1%) 
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Figure 2: Elevated platelet levels adversely affect cancer prognosis.  
 
 
Thrombocytosis at diagnosis (Platelets >450,000 cells/mcL) was 
associated with significantly worse overall survival (median 480 days vs. 625 
days, p = 0.007) and progression free interval (median 386 days vs. 440 days, p 
= 0.05). 
A total of 98 patients were identified who met criteria detailed in the 
methods section for full consideration of the question of whether platelet levels 
could be used as a biomarker of recurrence. (Figure 3) Following the completion 
of primary therapy, 86% of patients had a normal CA-125 level (< 35 U/mL) and 
100% of patients had a platelet count < 450,000 cells/mcL with a mean of 
206,000 cells/mcL. At the time of the clinical diagnosis of recurrence, CA-125 
was elevated in only 75% of patients. The mean platelet count at recurrence was 
262,000 cells/mcL, representing a 58% increase compared to the mean value at 
the conclusion of primary therapy (p < 0.05). Among patients with a normal CA-
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125 at time of recurrence, platelets increased by an average of 108,400/µL at 
recurrence compared to the end of primary therapy (49% increase, p < 0.05).  
 
 
 
 
Figure 3: Platelets as a biomarker of recurrence of disease.  
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Mean CA-125 and platelet levels are reflected at diagnosis, the lowest 
level during induction chemotherapy, at the completion of chemotherapy, the 
lowest level during post-therapy monitoring, and at the time of recurrence. 
Following the completion of primary therapy, 86% of patients had a normal CA-
125 level (< 35 U/mL) and 100% of patients had a platelet count < 450,000 
cells/mcL with a mean of 206,000 cells/mcL. At the time of the clinical diagnosis 
of recurrence, CA-125 was elevated in only 75% of patients. The mean platelet 
count at recurrence was 262,000 cells/mcL, representing a 58% increase 
compared to the mean value at the conclusion of primary therapy (p < 0.05). 
Among patients with a normal CA-125 at time of recurrence, platelets increased 
by an average of 108,400/µL at recurrence compared to the end of primary 
therapy (49% increase, p < 0.05). 
 
Platelets mediate in vitro apoptosis protection in tumor cells 
 Direct contact co-culture experiments were performed in which various 
cancer cell lines were plated in 6-well plates, serum-starved for 24 hours, and 
then variously treated with buffer control, docetaxel dosed according to 
previously published IC50, platelets dosed at 1 x 108 cells/mL, and platelets 
followed by docetaxel. After 72 hours of treatment, cells were processed for flow 
cytometry using Annexin and 7-aad staining to assess for total apoptosis. In the 
this first set of apoptosis experiments, platelets were included along with cancer 
cells in the analysis, and therefore it is understood that the additional 
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phosphatidylserine contribution of the platelets would increase the apoptosis 
score of groups containing platelets. (See Figure 4.) 
In A2780, platelets decreased apoptosis by 46.7% (p < 0.05) compared to 
buffer control, and platelets decreased apoptosis by 20.4% (p < 0.05) in the 
context of docetaxel. In HeyA8, platelets decreased apoptosis by 66.0% (p < 
0.05) compared to buffer control, and platelets decreased apoptosis by 53.6% (p 
< 0.05) in the context of docetaxel. In HeyA8-MDR, platelets decreased 
apoptosis by 70.0% (p < 0.05) compared to buffer control, and platelets 
decreased apoptosis by 66.8% (p < 0.05) in the context of docetaxel. In 
MDA.MB231, the most profound results were seen, as platelets decreased 
apoptosis by 90.3% (p < 0.05) compared to buffer control, and platelets 
decreased apoptosis by 62.1% (p < 0.05) in the context of docetaxel. In RUMG-
S, a slightly different pattern emerged, as platelets did not change apoptosis 
(10% increase, p = 0.33) compared to buffer control, however platelets continued 
to decrease apoptosis in the context of docetaxel, decreasing it by 33.9% (p < 
0.05). 
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Figure 4: Platelet co-culture with direct exposure of platelets to tumor cells offers 
protection against apoptosis.  
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Indirect contact co-culture experiments were performed in which various 
cancer cell lines were plated in 6-well plates, serum-starved for 24 hours, and 
then variously treated with buffer control, docetaxel dosed according to 
previously published IC50, platelets dosed at 1 x 108 cells/mL, and platelets 
followed by docetaxel. In this case, the tumor cells were separated from all 
components of the treatment by an insert with 0.4 mcm pores. After 72 hours of 
treatment, cells were processed for flow cytometry using Annexin and 7-aad 
staining to assess for total apoptosis. It is noted that platelets express 
phosphatidylserine that will also be marked by the Annexin. In the first set of 
apoptosis experiments, platelets were included along with cancer cells in the 
analysis, and therefore it is understood that the additional phosphatidylserine 
contribution of the platelets would increase the apoptosis score of groups 
containing platelets. In the present case, this effect should not be seen in these 
data, as platelets were kept separated from the cancer cells by the barrier. (See 
Figure 5.) 
In A2780, platelets decreased apoptosis 60.8% (p < 0.05) compared to 
buffer control, and platelets decreased apoptosis 17.4% (p < 0.05) in the context 
of docetaxel. In MDA.MB231, platelets decreased apoptosis 52.3% (p < 0.05) 
compared to buffer control, and platelets decreased apoptosis 28.0% (p < 0.05) 
in the context of docetaxel. In 2774, platelets decreased apoptosis 25.3% (p < 
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0.05) compared to buffer control, and platelets decreased apoptosis 27.5% (p < 
0.05) in the context of docetaxel. 
 
 
 
Figure 5: Platelet co-culture with indirect exposure of platelets to tumor cells 
offers protection against apoptosis.  
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Platelets mediate in vitro increases in proliferation in tumor cells 
 Direct contact co-culture experiments were conducted in which various 
cancer cell lines were plated in 6-well plates, serum-starved for 24 hours, and 
then treated with either control buffer or platelets at a density of 1 x 108 cells/mL 
for 24 hours. After treatment, they were incubated with EdU and processed as 
described above for flow cytometric evaluation of EdU incorporation as a proxy 
for degree of proliferation. (See Figure 6.) 
Using HeyA8, co-culture with platelets resulted in mean increase in 
proliferation of 257.5% +/- 8.13% (p < 0.05) compared to control. Using SKOV3-
Ip1, co-culture with platelets resulted in mean increase in proliferation of 78.9% 
+/- 1.47% (p < 0.05) compared to control. Using OVCAR5, co-culture with 
platelets resulted in mean increase in proliferation of 84.9% +/- 9.58% (p < 0.05) 
compared to control. Using ID8, co-culture with platelets resulted in mean 
increase in proliferation of 221.6% +/- 21.9% (p < 0.05) compared to control.  
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Figure 6: Platelet co-culture mediates increased tumor cell proliferation.  
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Platelets mediate in vitro increases in migration of tumor cells 
 Co-culture experiments were conducted in which various cancer cell lines 
were co-cultured with either control buffer or platelets at a density of 1 x 108 
cells/mL using a modified Boyden chamber system for 6 hours. After incubation, 
fields were scored for migration (Figure 7).  
Compared to buffer control, platelet co-culture with A2780 caused a 2.6-
fold increase in the rate of migration (p < 0.05), platelet co-culture with HeyA8 
caused a 2.8-fold increase in the rate of migration (p < 0.05), and platelet co-
culture with 2774 caused a 2.1-fold increase in the rate of migration (p < 
0.05).(37) 
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Figure 7: Platelet co-culture mediates increased tumor cell migration.  
 
 
 
 
 
 
 
 
 
 
 74 
 
Hypoxia induces platelet-activating conditions in vitro, and effects of platelet 
exposure are maintained in hypoxic conditions in vitro. 
 Hypoxia is recognized as a mediator of angiogenic signaling that may 
contribute to changes in the tumor environment, both on a cellular and on an 
ecological level that may contribute to resistance to anti-angiogenic therapy. 
Given the apparent regulatory effects of platelets on angiogenesis, given platelet 
activity in wound healing, and given the powerful effects of ADP on platelet 
activation, we determined to examine the effects of hypoxia on cells and 
conditioned media. Specifically, SKOV3-IP1 was cultured in 10 cm plates in 
serum-free media in hypoxic and normoxic environments, and conditioned media 
was assessed at 24, 48, and 72 hours for the platelet-activating compound 
adenosine di-phosphate (ADP). (See Figure 8.) 
At 24 hours, media from normoxic-cultured cells had 2.91 +/- 0.02 mM 
ADP compared to media from hypoxic-cultured cells that had 5.80 +/- 0.01 mM 
ADP (p < 0.05). At 48 hours, media from normoxic-cultured cells had 2.98 +/- 
0.06 mM ADP compared to media from hypoxic-cultured cells that had 12.68 +/- 
0.14 mM ADP (p < 0.05). At 72 hours, media from normoxic-cultured cells had 
2.10 +/- 0.02 mM ADP compared to media from hypoxic-cultured cells that had 
11.76 +/- 0.08 mM ADP (p < 0.05). 
 
 
 
 75 
 
 
Figure 8: Conditioned media from SKOV-3 exposed to normoxic and hypoxic 
conditions.  
 
 The gross phenotypic effects of hypoxia and platelet-exposure were 
assessed in HeyA8 cells plated in 10 cm plates, placed in a serum-free media, 
and grown in normoxic versus hypoxic environments, with and without platelets 
dosed at 1 x 108 cells/mL. (See Figure 9.)  
Comparing cells not exposed to platelets in the normoxic versus hypoxic 
environments, cell counts per 100x field at 72 hours were very similar, however 
cells in the hypoxic environment were less spiculated and had fewer cell-to-cell 
contacts compared to the normoxic environment. In both the normoxic and 
hypoxic contexts, co-culture with platelets resulted in a significant increase in cell 
density and eliminated the apparent differences in visual phenotype. 
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Figure 9: Gross phenotypic effects of hypoxia at 72 hours on HeyA8 exposed to 
hypoxic versus normoxic environments +/- platelets.  
  
Taxane biodistribution in whole blood. 
 In order to consider whether platelets may be sequestering docetaxel to a 
degree that might explain the findings of the in vitro apoptosis experiments, 
human blood was inoculated ex vivo with docetaxel at two different 
concentrations (“high” dose = 5 mcg/mL and “low” dose = 1 mcg/mL) and 
incubated for 0.5 hr, 1.0 hr, 1.5 hr, 2.0 hr, 3.0 hr, 4.0 hr, 6.0 hr, 8.0 hr, and 24 hr. 
Biodistribution was determined by HPLC as described in the methods. (See 
Figure 10.) 
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 Comparing docetaxel levels across time-points within groups, there were 
no significant differences between time-points, however there were remarkable 
differences between groups. Across all time-points, in the platelet fraction 
exposed to low-dose docetaxel, no docetaxel was detected in any of these 
samples at any time-point. In contrast, the low-dose exposed platelet-free plasma 
fractions and whole plasma fractions were not significantly different (1261 +/- 7.3 
ng/mL versus 1211 +/- 7.0 ng/mL, p = 0.12) across all time-points. The platelet 
fraction exposed to high-dose docetaxel had detectable levels of 48.56 +/- 3.06 
ng/mL, which actually falls below the lower limit of quantifiability. In contrast, the 
high-dose exposed platelet-free plasma fractions and whole plasma fractions 
were not significantly different (5123 +/- 37.9 ng/mL versus 5191 +/- 23 ng/mL, p 
= 0.62) across all time-points. 
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Figure 10: Docetaxel biodistribution in whole plasma compared to platelet-free 
plasma compared to platelets. 
 
Platelet infiltration into tumor 
 In order to query whether platelets could plausibly be exposed to cancer 
cells in a biological system, e.g. in an organism with a growing tumor, nude mice 
were inoculated with the ovarian cancer cell line 2774. When tumor was palpable 
by physical examination of the mouse abdomen, the mouse was anesthetized 
and sacrificed by intravital fixation. Frozen tumor sections were taken for 
immune-fluorescence. Co-staining was performed for mouse-CD31 and for the 
mouse GP1b-beta subunit of the GP1b-V-IX complex. (See Figure 11.) 
The numbers of infiltrating platelets were counted in representative 200x 
fields. It was found that representative tumor sections had a mean 69.3 +/- 14.5 
cells positive for GP1b-beta staining suggesting platelet infiltration into the tumor. 
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This compared to almost no platelets observed in normal peritoneum and only a 
slightly increased number seen in a model of induced peritonitis (37). 
 
 
Figure 11: Platelets infiltrate tumor.  
 
Modulation of platelet levels correlates with tumor growth, tumor spread, and 
chemotherapeutic efficacy. 
 Two experiments were performed to query the effects of platelet levels on 
tumor growth and chemotherapeutic efficacy using our orthotopic model of 
ovarian cancer in nude mice. 
 In the first experiment, mice were inoculated with A2780 on Day 0 and 
treatment was initiated on Day 7. Control mice were given a control IgG. The 
second groups of mice were given a platelet-depleting IgG previously validated in 
our lab. The third group was given control IgG and docetaxel. The fourth group 
was given platelet-depleting IgG in addition to docetaxel. Mice were sacrificed 
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when a significant number appeared moribund from disease. At necropsy, data 
was taken regarding tumor nodule number and aggregate tumor weight. (See 
Figure 12.)  
Mice treated with control IgG had a mean aggregate tumor weight of 2.01 
+/- 0.14 g per mouse and a mean number of tumor nodules of 25.7 +/- 2.1 
nodules per mouse. Mice treated with platelet-depleting IgG had a mean 
aggregate tumor weight of 0.71 +/- 0.07 g per mouse and a mean number of 
tumor nodules of 11.1 +/- 1.2 nodules per mouse. Compared to control, mice 
treated with the platelet-depleting IgG had a significantly lower aggregate tumor 
weight (p < 0.05) and number of tumor nodules (p < 0.05). Mice treated with 
control IgG and docetaxel had a mean aggregate tumor weight of 0.60 +/- 0.07 g 
per mouse and a mean number of nodules of 4.9 +/- 0.7 nodules per mouse. The 
mean aggregate tumor weight for the mice treated with the platelet-depleting IgG 
and the control IgG plus docetaxel were not significantly different (p = 0.70). The 
mean number of nodules showed a non-significant trend toward a decrease 
when the platelet-depleting IgG mice were compared to those treated with control 
IgG and docetaxel (p = 0.13). Mice treated with platelet-depleting IgG and 
docetaxel had a mean aggregate tumor weight of 0.23 +/- 0.02 g per mouse and 
a mean number of tumor nodules of 2.0 +/- 0.1 nodules per mouse. Compared to 
mice treated with control IgG and docetaxel, these decreases in mean aggregate 
tumor weight (p = 0.09) and nodule number per mouse (p = 0.17) represented 
trends toward significance. 
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Figure 12: Effect of platelet-depletion on docetaxel chemotherapy in mice with 
orthotopically-inoculated A2780. 
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 In the second experiment, mice were inoculated with SKOV3-IP1 on Day 0 
and treatment was initiated on Day 7. Control mice were given a control IgG. The 
second groups of mice were given a platelet-depleting IgG previously validated in 
our lab. The third group was given platelet transfusion as described in the 
methods section. The fourth group was given control IgG in addition to docetaxel. 
The fifth group was given platelet-depleting IgG and docetaxel. The sixth group 
was given platelet transfusion and docetaxel. Mice were sacrificed when a 
significant number appeared moribund from disease. At necropsy, data was 
taken regarding tumor nodule number and aggregate tumor weight. It is noted 
that this experiment was ended because of the condition of the platelet-
transfused mice. (See Figure 13.)  
 Mice treated with control IgG had a mean aggregate tumor weight of 0.37 
+/- 0.037 g per mouse and a mean number of tumor nodules of 4.86 +/- 0.29 
nodules per mouse. Mice treated with platelet-depleting IgG had a mean 
aggregate tumor weight of 0.21 +/- 0.017 g per mouse and a mean number of 
tumor nodules of 4.50 +/- 0.41 nodules per mouse. Compared to control, mice 
treated with the platelet-depleting IgG had a non-significant trend toward lower 
aggregate tumor weight (p = 0.15), while the number of tumor nodules was 
similar (p = 0.81). Mice treated with platelet transfusion had a mean aggregate 
tumor weight of 0.87 +/- 0.054 g and mean number of nodules of 13.25 +/- 1.13 
nodules per mouse. Compared to control, platelet transfused mice had a 
significant increase in mean tumor weight (p < 0.05) and a significant increase in 
mean number of tumor nodules per mouse (p < 0.05). Mice treated with control 
 83 
 
IgG and docetaxel had a mean aggregate tumor weight of 0.17 +/- 0.007 g per 
mouse and a mean number of tumor nodules of 2.22 +/- 0.11 nodules per 
mouse. Compared to control, mice treated with control IgG and docetaxel had a 
significant decrease in mean tumor weight (p < 0.05) and a significant decrease 
in mean number of tumor nodules per mouse (p < 0.05). By contrast, compared 
to mice treated with platelet-depleting antibody, mice treated with control IgG and 
docetaxel there was only a statistical trend toward decreased mean tumor weight 
(p = 0.07) and a statistical trend toward decreased mean number of tumor 
nodules per mouse (p = 0.07). Mice treated with platelet-depleting antibody in 
addition to docetaxel had a mean tumor weight of 0.057 +/- 0.005 g per mouse 
and a mean number of tumor nodules of 2.57 +/- 0.22 nodules per mouse. 
Compared to the mice treated with control IgG and docetaxel, there was a 
significant decrease in mean aggregate tumor weight (p < 0.05). Mice treated 
with platelet transfusion and docetaxel had a mean aggregate tumor weight of 
0.47 +/- 0.043 g per mouse and a mean number of tumor nodules of 4.0 +/- 0.53 
nodules per mouse. Compared to mice treated with control IgG and docetaxel, 
there was a significant increase in mean tumor weight (p < 0.05) and a non-
significant trend toward an increase in mean number of tumor nodules (p = 0.21). 
Compared to mice treated with control IgG only, the mice treated with both 
platelet transfusion and docetaxel had statistically similar mean aggregate tumor 
weights (p = 0.55) and mean nodule number (p = 0.61). 
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Figure 13: Effect of platelet-depletion and platelet-transfusion on docetaxel 
chemotherapy in mice with orthotopically-inoculated SKOV3-IP1. 
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Platelet activation is necessary for observed in vitro effects. 
 In order to determine whether platelet activation was necessary for the 
effects observed, the proliferation and apoptosis experiments described 
previously were repeated using the cell line HeyA8, in this cycle including a 
group treated with an equivalent number of platelets fixed with 
paraformaldehyde. (See Figure 14.) 
 The cell line HeyA8 was plated in 6-well plates and co-cultured with 
routine buffer control, plasma-free platelets (1 x 108 cells/mL), platelets fixed with 
1% paraformaldehyde as described in the methods section, or a buffer 
processed including paraformaldehyde in parallel to the platelets prepared by 
paraformaldehyde fixation. Cells were analyzed by flow cytometry for apoptosis 
after 72 hours and for proliferation after 24 hours. Cells cultured with routine 
buffer control had a baseline apoptotic rate of 9.6 +/- 0.3%. Cells co-cultured with 
platelets had an apoptotic rate of 3.3 +/- 0.08%, which was significantly 
decreased compared to control (p < 0.05). The cells incubated with the 
paraformaldehyde prepared buffer and with the paraformaldehyde-fixed platelets 
had apoptosis rates of 10.6 +/- 0.2% and 10.4 +/- 0.2% respectively. In both 
cases, this was not significantly different than the control group (p = 0.20 and p = 
0.28, respectively). Cells cultured with standard buffer had a baseline 
proliferation rate of 11.3 +/- 0.25%, which was significantly increased to 59.0 +/- 
0.47% (p < 0.05) with co-culture with platelets. Paraformaldehyde fixation of 
platelets abrogated the increase in proliferation, decreasing the rate to 14.2 +/- 
0.68%, which was not significantly different than control (p = 0.084) 
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Figure 14: Apoptosis protection and proliferation augmentation effects of platelet 
co-culture are eliminated by platelet fixation. 
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 In order to consider what options may be clinically available to block 
platelet activation, the proliferation end-point was re-examined, but instead of 
blocking platelet activation with highly-toxic paraformaldehyde, aspirin and a 
small molecule inhibitor of focal adhesion kinase were used to block platelet 
activation. (See Figures 15 and 16.) 
 SKOV3-IP1 cells were co-cultured with control buffer, platelets, aspirin, 
and aspirin—pretreated platelets. After 24 hours of treatment, flow cytometric 
analysis was performed to assess degree of proliferation. In the control group the 
proliferative rate was 21.7 +/- 0.72%. In the platelet-treated group, the 
proliferative rate was 34.1 +/- 0.94%. In the aspirin treated group, the proliferative 
rate was 23.1 +/- 1.73%. In the cells treated with both aspirin and platelets, the 
proliferation rate was 27.3 +/- 2.05%. The increase in proliferation between 
control and platelet-treatment was statistically significant (p < 0.05). Interestingly, 
because aspirin incompletely abrogated platelet-induced proliferation, and 
because variances were relatively large, the proliferation rate of the cells treated 
with aspirin and platelets was not significantly different from the primary control 
(p = 0.22) or from the platelet-treated tumor cells without aspirin (p = 0.157). 
 HeyA8 cells were co-cultured with control buffer, platelets, FAK-inhibitor, 
and FAK-inhibitor plus platelets. After 24 hours of treatment, flow cytometric 
analysis was performed to assess degree of proliferation. In the control group the 
proliferative rate was 14.5 +/- 1.94%. In the platelet-treated group, the 
proliferative rate was 50.2 +/- 2.66%. In the FAK-inhibitor treated group, the 
proliferative rate was 17.2 +/- 2.15%. In the cells treated with both FAK-inhibitor 
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and platelets, the proliferation rate was 16.9 +/- 1.33%. The increase in 
proliferation between control and platelet-treatment was statistically significant (p 
< 0.05). By way of comparison, there were no significant differences between the 
other three groups. Comparing the control to the FAK-inhibitor plus platelets, p = 
0.58. 
 
 
 
Figure 15: Blockade of the tumor cell proliferative response to platelets with 
aspirin. 
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Figure 16: Blockade of the tumor cell proliferative response to platelets with the 
FAK-inhibitor. 
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Platelet-derived growth factor (PDGF) and transforming growth factor beta-1 
(TGFB1) are involved in the observed mitogenic signaling. 
 In order to validate the causality of platelet-derived signaling factors in the 
proliferation and apoptosis-protection observed in our experiments, siRNA 
transfection methods were validated to knockdown expression of platelet-derived 
growth factor receptor alpha (PDGFRA) and transforming growth factor beta-1 
receptor (TGFBR1), as these factors are known to be released from platelets on 
activation. Transfection was used to attempt to demonstrate that these pathways 
could be blockaded. (See Figures 17 and 18.) 
 After validation of siRNA knockdown, reverse transfection was performed 
on HeyA8 cells, and 48 hours later, treatment with control buffer or platelets was 
initiated. After 24 hours of treatment, flow cytometric analyses for proliferation 
was performed. As anticipated, in the cells transfected with control siRNA, 
platelet co-culture resulted in a significant increase in proliferation (5.41% versus 
23.35%, p < 0.05). There was no difference in proliferation between the cells 
transfected with control siRNA compared to PDGFRA siRNA (5.41% versus 
5.00%) that were not exposed to platelets. However, in the cells transfected with 
PDGFRA siRNA, cells exposed to platelets only demonstrated an increase from 
5.00% proliferation to 17.13% proliferation (p < 0.05). While that increase was 
significant, it was not as large an increase in proliferation as that seen in the cells 
transfected with control siRNA and exposed to platelets (23.25% versus 17.13%, 
p < 0.05). 
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 After validation of siRNA knockdown, double transfection as described in 
the methods section was performed on SKOV3-IP1 cells. Immediately following 
the second-phase of the transfection, treatment was initiated with control buffer, 
docetaxel 5 nM, platelets 1 x 108 cells/mL, or platelets followed immediately by 
docetaxel. In the cells transfected with control siRNA, baseline apoptosis was 
34.3 +/- 1.04%, docetaxel-mediated apoptosis was 60.8 +/- 1.05%, apoptosis 
after platelet co-culture was markedly decreased at 6.07 +/- 0.32% (p < 0.05 
compared to control), and platelets also decreased docetaxel-mediated 
apoptosis to 40.2 +/- 0.86% (p < 0.05 compared to docetaxel alone). In cells 
transfected with siRNA targeted to TGFBR1, baseline apoptosis was similar to 
control siRNA transfection at 36.4 +/- 0.65%. Docetaxel-mediated apoptosis was 
also similar to control siRNA transfected cells at 64.7 +/- 1.73%. However, 
platelet co-culture only decreased apoptosis to 23.3 +/- 0.39% compared to 
6.07% in the control siRNA transfected cells (p < 0.05), representing a 60.9% 
blockade of platelet-mediated apoptosis protection. Likewise, platelet co-culture 
in the context of docetaxel only decreased apoptosis to 50.4 +/- 1.71% in 
TGFBR1 transfected cells compared to control siRNA transfected cells, 
representing a 69% return of apoptosis (p < 0.05). 
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Figure 17: Proliferative response to platelets is partially mediated by PDGFRA 
signaling. 
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Figure 18: Apoptosis protection from platelets is partially mediated by TGFBR1 
signaling. 
 
Aspirin can block in vivo effects of platelet transfusion on tumor growth. 
 In order to consider the mechanism of platelet effect on tumor growth and 
spread, we used our orthotopic model of ovarian cancer in nude mice to query 
whether those effects could be blocked by aspirin therapy. Nude mice were 
inoculated with A2780 on Day 0 and treatment was started on Day 7. Control 
animals were untreated. The second group received aspirin therapy as described 
in the methods section. The third group received platelet transfusion as 
described in the methods section. The fourth group was given transfusions of 
aspirinized platelets per the protocol described in the methods section. When a 
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substantial number of mice became moribund, the animals were sacrificed. (See 
Figures 19-22.) 
 Control animals with no treatment had a mean aggregate tumor weight of 
2.14 +/- 0.50 g per mouse and a mean number of tumor nodules of 20.57 +/- 
6.91 nodules per mouse. Animals treated with aspirin were not statistically 
different, having a mean aggregate tumor weight of 1.93 +/- 0.26 g per mouse 
and a mean number of tumor nodules of 23.0 +/- 4.51 nodules per mouse. Mice 
receiving platelet transfusions had a significantly increased mean aggregate 
tumor weight of 4.11 +/- 0.59 g per mouse (p < 0.05 compared to control and 
aspirin-treated groups) and mean number of tumor nodules of 62.3 +/- 9.86 
nodules per mouse (p < 0.05 compared to control and aspirin-treated groups). 
Transfusion of aspirinized platelets did not have the same effect as non-
aspirinized platelets and was statistically similar to the control and aspirin treated 
groups; mean tumor weight was 2.06 +/- 0.34 g per mouse and mean number of 
nodules was 24.4 +/- 6.79 nodules per mouse (both p < 0.05 compared to 
platelet transfused mice). 
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Figure 19: Aspirin treatment blocks in vivo effects of aspirin therapy. 
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 The initial evaluation of tumor vasculature was performed based on 
conventional scoring of microvascular density as determined by identified 
clusters of 3 or more CD31-positive cells. Based on this system, tumor from 
platelet transfused mice demonstrated a significant decrease in microvascular 
density per 200x field, control 19.07 +/- 0.39 vessels per HPF versus 14.0 +/- 
0.25 vessels per HPF, p < 0.05. By contrast, the aspirin treated mice had a 
microvascular density of 16 +/- 0.56 (p = 0.28) and the mice treated with 
aspirinized platelets had a microvascular density of 14.8 +/- 0.39, which 
approached statistical significance at p = 0.059. These differences were not 
overwhelming and obligated more careful consideration. 
 As a contrasting analysis, we re-scored the CD31 considering the concept 
of vascular stabilization by scoring for the ratio of lumen-containing CD31-
positive clusters to non-lumen-containing clusters. In this case, platelet-
transfused mice had tumors with a significantly higher ratio, scoring a mean 2.56 
+/- 0.117 compared to the control value of 1.038 +/- 0.063, p < 0.05. By contrast, 
the aspirin-only treated mice had a mean ratio of 1.039 +/- 0.043, which was 
statistically indistinguishable from control, p = 0.997. The tumor from the mice 
treated with aspirinized platelets had a ratio of 1.91 +/- 0.147 that trended toward 
a significant increase compared to control with p = 0.20. 
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Figure 20: Platelet transfusion normalizes tumor vasculature. 
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 Tumor harvested from the mice at the time of sacrificed was assessed 
using Ki67 immunohistochemistry for ratio of proliferating nuclei to total nuclei 
counted in a 200x field (proliferative index). The tumor from control animals was 
noted to have a proliferative index of 66.3 +/- 0.77%. Aspirin significantly 
decreased this rate of proliferation by itself, with the aspirin-only treated mice 
scoring 56.8 +/- 0.77% (p < 0.05). Platelet transfusion had the opposite effect, 
increasing the mean proliferative index to 82.9 +/- 0.43% (p < 0.05). Transfusion 
of aspirinized platelets resulted in a non-significant trend toward an increased 
proliferative index at 72.0 +/- 0.62% (p = 0.14), suggesting that aspirinized 
platelets may have had an incompletely blocked effect. Comparing the tumor of 
platelet-transfused mice to tumor from mice that had been transfused with 
aspirinized platelets, the difference in proliferative index (82.9% versus 72.0%, p 
< 0.05) was significant, again suggesting that aspirin at least partially blocked he 
effects attributable to platelet transfusion. 
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Figure 21: Platelet transfusion increases tumor cell proliferation that is partially 
blocked by aspirin. 
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 In order to query whether platelet transfusion would impact tumor cell 
apoptosis, ex vivo tumor from treated animals was immunostained for activated 
caspase-3 that was scored based on the number of positive cells per 200x field. 
Tumor from control animals demonstrated a mean of 28.1 +/- 3.43 positive cells 
per 200x field. Tumor from aspirin-treated animals had a nearly identical mean of 
28.9 +/- 2.32 positive cells per 200x field. In sharp contrast, tumor from platelet-
transfused animals had a statistically significantly lower rate of positive 
(apoptotic) cells at 17.6 +/- 2.10 positive cells per 200x field (p < 0.05). 
Interestingly, the tumor from the mice given transfusions with aspirinized platelets 
had a rate of positivity (22.5 +/- 1.62 positive per 200x field) greater than that of 
the platelet-transfusion mice and lower than that of the control and aspirin-treated 
mice (p = 0.113 compared to control and p = 0.098 compared to platelet-
transfused mice). However, the data again suggest that aspirin was only able to 
partially block the effects of platelet transfusion on this orthotopic model of 
ovarian cancer. 
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Figure 22: Platelet transfusion results in decreased tumor cell apoptosis. 
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Acceleration of tumor growth after withdrawal of anti-angiogenic agents 
 As discussed in the introduction, response to anti-angiogenic therapy has 
been modest in the clinical setting, and recent pre-clinical models have even 
suggested a rebound in tumor growth following the withdrawal of certain anti-
angiogenic agents. 
In consideration of this concern, and given the probability that micro-
environmental factors may play a central role in these phenomena, we initially 
sought to establish a pre-clinical model in which we could study the effects of 
anti-angiogenic therapy on tumor. In order to query the phenomenon of 
resistance to anti-angiogenic therapy and rebound tumor growth that has recently 
been described in the literature, we sought to establish a working in vivo model. 
Ultimately, the goal was to develop working in vivo models of both antibody-
based treatment resistance (e.g. bevacizumab) and small molecule inhibitor-
based treatment resistance (e.g. pazopanib). For our first experiment, we started 
with pazopanib because it is a well-tolerated and studied drug in pre-clinical 
models and is of current interest in early-phase ovarian cancer trials. We 
inoculated nude mice with SKOV3-IP1 on Day 0. In the first group of mice, the 
animals were treated with pazopanib for 7 days prior to Day 0 inoculation with 
tumor. Two other groups were given drug vehicle as controls from Day 7-14 and 
starting on day 7 for the duration of the experiment. A fourth group was given 
pazopanib daily from Day 7-14. The fifth group was given pazopanib daily 
starting on day 7 for the duration of the experiment. Animals were sacrificed 
when a significant number appeared to be suffering morbidity related to tumor 
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burden. Data were taken with respect to aggregate tumor weight and the number 
of identified tumor nodules. (See Figure 23.) 
 Mice were sacrificed primarily related to morbidity seen in the mice treated 
with pazopanib for only seven days. There were no statistical differences seen 
between mean aggregate tumor weight or number of tumor nodules for the mice 
pre-treated with pazopanib (0.30 +/- 0.053 g/mouse; 10 +/- 2.22 nodules/mouse), 
the mice treated with vehicle for 7 days (0.35 +/- 0.06 g/mouse; 12.9 +/- 3.34 
nodules/mouse), and the mice treated with vehicle continuously starting at Day 7 
(0.32 +/- 0.06 g/mouse; 12.2 +/- 2.75 nodules/mouse). Choosing a representative 
vehicle control for comparison, treatment with continuous pazopanib resulted in a 
decreased mean aggregate tumor weight (0.11 +/- 0.01 g/mouse versus 0.35 +/- 
0.06 g/mouse, p < 0.05) and decreased number of tumor nodules that 
approached statistical significance (6 +/- 0.97 nodules/mouse versus 12.9 +/- 
3.34 nodules/mouse, p = 0.06). In sharp contrast, treatment of the mice with 
pazopanib from days 7-14 resulted in increased aggregate tumor weight 
compared to control that approached statistical significance (0.54 +/- 0.05 
g/mouse versus 0.35 +/- 0.06 g/mouse, p = 0.08) and an increased average 
number of tumor nodules that was non-significant but of interest (17.0 +/- 1.87 
versus 12.9 +/- 3.34 nodules/mouse, p = 0.29). The differences in mean tumor 
weight and mean number of nodules between animals treated continuously with 
pazopanib and for 7 days with pazopanib were both statistically significant, p < 
0.05. 
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Figure 23: Short-term anti-angiogenic therapy results in acceleration of tumor 
growth. 
 
 
 
 105 
 
Acceleration of tumor growth after withdrawal of anti-angiogenic agents is 
abrogated by FAK blockade. 
 Based on the preliminary finding that short-term treatment with pazopanib 
in our orthotopic model of ovarian cancer resulted in an increase in the aggregate 
tumor mass and number of tumor nodules per mouse compared to control and to 
continuously treated animals, based on the knowledge that FAK-inhibition is 
effective in platelets, based on demonstrated platelet infiltration into tumor, and 
based on literature suggesting that the absence of focal adhesion kinase 
signaling in platelets leads to impaired migration, we formed a two-fold 
hypothesis: (1) short term anti-angiogenic therapy leads to local hypoxia and 
increased local activation of platelets through ADP-driven mechanisms, and (2) 
that impairment of FAK-mediated signaling would lead to impaired platelet 
infiltration into tumor, correlating with a blockade of the observed “rebound” 
effect. 
 Based on this hypothesis, a series of in vivo studies were designed 
utilizing the orthotopic model of ovarian cancer in nude mice. In the first 
experiment, nude mice were inoculated with SKOV3-IP1 on Day 0 and treatment 
was initiated on Day 7. Control mice were untreated. In groups 2-4, pazopanib 
was initiated and given daily. In groups 5-7, bevacizumab was administered on a 
twice-weekly schedule. In groups 2 and 5, treatment was discontinued after 1 
week. In groups 3 and 6, treatment was continued for the duration of the 
experiment. In groups 4 and 7, treatment of the anti-angiogenic medication was 
discontinued after 1 week, and the FAK-inhibitor was administered on a daily 
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basis thereafter. The experiment was ended and animals sacrificed when a 
significant degree of cancer-related morbidity was observed. (See Figure 24.) 
 In the second experiment, the design detailed above was replicated using 
the cell line HeyA8. (See Figure 25.) 
 In the third experiment, nude mice were inoculated with SKOV3-IP1 and 
tumor was allowed to develop until palpable. One group was an untreated 
control, one group was given twice-weekly bevacizumab, one group was given 
daily pazopanib, and one group was given FAK-inhibitor. After one week of 
therapy, animals were sacrificed and tumor was harvested for analysis. Blood 
was also taken at that time for CBC. Tumor was analyzed by 
immunofluorescence to determine whether the platelet infiltration was altered 
either by the use of anti-angiogenic agents or the use of the FAK-inhibitor. (See 
Figure 26.) 
 In this first experiment, mice were inoculated with SKOV3-IP1 prior to the 
initiation of therapy, and therapy was as described above. The experiment was 
stopped because of the condition of the mice treated with only 7 days of 
pazopanib. Compared to the untreated control mice, animals treated with 
continuous pazopanib were noted to have a significant decrease in the aggregate 
mean tumor weight (0.95 +/- 0.22 g/mouse versus 0.26 +/- 0.06 g/mouse, p < 
0.05) and a trend toward a significantly decreased number of tumor nodules 
(15.33 +/- 2.8 nodules/mouse versus 8.7 +/- 1.58 nodules/mouse, p = 0.152). By 
contrast, mice treated with only 7 days of pazopanib had increased aggregate 
mean tumor weight (0.95 +/- 0.22 g/mouse versus 1.39 +/- 0.27 g/mouse, p = 
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0.22) and number of nodules (15.33 +/- 2.8 nodules/mouse versus 29.11 +/- 6.36 
nodules/mouse, p = 0.065) that trend toward statistical significance. Mice treated 
with short-term pazopanib followed by the FAK-inhibitor also had significantly 
decreased tumor weight compared to control (0.95 +/- 0.22 g/mouse versus 0.26 
+/- 0.05 g/mouse, p < 0.05) and decreased number of nodules compared to 
control (15.33 +/- 2.8 nodules/mouse versus 4.87 +/- 0.50 nodules/mouse, p = 
0.065). 
In a similar fashion, compared to untreated control animals, mice treated 
with only 7 days of bevacizumab experienced non-significant increases in mean 
aggregate tumor weight and number of nodules. In contrast, mice treated with 
continuous bevacizumab were noted to have decreased aggregate mean tumor 
weight compared to control (0.95 +/- 0.22 g/mouse versus 0.29 +/- 0.06 g/mouse, 
p < 0.05). Similarly, animals treated with 7 days of bevacizumab followed by the 
FAK-inhibitor were noted to have decreased aggregate mean tumor weight 
compared to control (0.95 +/- 0.22 g/mouse versus 0.14 +/- 0.06 g/mouse, p < 
0.05). 
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Figure 24: Short-term anti-angiogenic therapy accelerates tumor growth, and the 
effect is blocked by the FAK-inhibitor. 
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In the second experiment, mice were inoculated with HeyA8 prior to the 
initiation of therapy, and therapy was as described above. The experiment was 
stopped because of the condition of the mice treated with only 7 days of 
pazopanib. Compared to the untreated control mice, animals treated with 
continuous pazopanib were noted to have a significant decrease in the aggregate 
mean tumor weight (0.55 +/- 0.16 g/mouse versus 0.19 +/- 0.03 g/mouse, p < 
0.05). By contrast, mice treated with only 7 days of pazopanib had increased 
aggregate mean tumor weight (0.55 +/- 0.16 g/mouse versus 1.51 +/- 0.35 
g/mouse, p < 0.05). Mice treated with short-term pazopanib followed by the FAK-
inhibitor also had decreased tumor weight compared to control (0.55 +/- 0.16 
g/mouse versus 0.29 +/- 0.14 g/mouse, p = 0.24) that trended toward 
significance and was not statistically distinct from mice treated with continuous 
pazopanib (p = 0.50). 
In a similar fashion, compared to untreated control animals, mice treated 
with only 7 days of bevacizumab experienced increases in mean aggregate 
tumor weight that trended toward significance (0.55 +/- 0.16 g/mouse versus 1.05 
+/- 0.33 g/mouse, p = 0.182). In contrast, mice treated with continuous 
bevacizumab were noted to have decreased aggregate mean tumor weight 
compared to control (0.55 +/- 0.16 g/mouse versus 0.31 +/- 0.08 g/mouse, p = 
0.21). Similarly, animals treated with 7 days of bevacizumab followed by the 
FAK-inhibitor were noted to have decreased aggregate mean tumor weight 
compared to control (0.55 +/- 0.16 g/mouse versus 0.18 +/- 0.05 g/mouse, p = 
0.060). 
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Figure 25: Short-term anti-angiogenic therapy accelerates tumor growth, and the 
effect is blocked by the FAK-inhibitor. 
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 In animals inoculated with SKOV3-IP1, after tumor was palpable, animals 
were treated for one week with nothing, bevacizumab, pazopanib, or the 
available FAK-inhibitor. At the end of the week, animals were sacrificed. Blood 
was taken for CBC. All groups had similar platelet levels except for the animals 
treated with bevacizumab. In this case, compared to control, bevacizumab-
treated animals had an elevated platelet level compared to control that 
approached statistical significance (1399 +/- 18 cells/mcL versus 1746 +/- 91 
cells/mcL, p = 0.07). Tumor was harvested and flash frozen after 
paraformaldehyde intra-vital fixation. Double-immune fluorescence staining of 
tumor sections were significant for both intravascular and intra-tumor platelet 
accumulation that was scored according to the number of discrete aggregates 
per 200x field. Compared to the control mice, those treated with bevacizumab 
had an increased number of platelet aggregates that reached statistical 
significance (3.88 +/- 0.17 aggregates/200x versus 14 +/- 0.55 aggregates/200x, 
p < 0.05). Compared to the control mice, those treated with pazopanib had an 
increased number of platelet aggregates that approached statistical significance 
(3.88 +/- 0.17 aggregates/200x versus 5.83 +/- 0.17 aggregates/200x, p = 0.06). 
In contrast, animals treated with FAK-inhibitor had a decreased number of 
platelet aggregates that did not reach statistical significance (3.88 +/- 0.17 
aggregates/200x versus 2.93 +/- 0.19 aggregates/200x, p = 0.45). 
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Figure 26: Short-term anti-angiogenic therapy causes increased platelet invasion 
into tumor that is blocked by the FAK-inhibitor. 
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Discussion 
 Over the past 30 years, significant time, effort, and money have been 
spent in an on-going fight to decrease mortality related to cancer. Aside from 
some notable victories, e.g. imatinib therapy for chronic myelogenous leukemia, 
progress has been incremental, and progress has been significantly less than 
that seen in other chronic diseases of aging. Of late, there has been significant 
focus placed on determining a more detailed understanding of the detailed 
molecular biology of cancer. This point of view may be reductionist, and it is at 
significant risk of failing to recognize both the dizzying heterogeneity of a cancer, 
but is also the myriad interactions of those heterogeneous tumor cells with 
otherwise normally functioning cells and systems of the human body. This work 
is not a rejection of pathway-level thinking, however the logic of the current work 
operates at the level of cellular systems and considers net effect at the level of 
population and ecology; we specifically consider the contribution of platelets to 
selection and promotion of clonal populations via mitogenicity and the 
augmentation of angiogenesis. 
 
 One of the primary reasons that cancer has proven difficult to treat, 
including in the case of ovarian cancer, is that we continue to lack adequate 
biomarkers to provide early identification of more readily treated disease. In the 
present work, we provide evidence to support the notion that platelet levels may 
be considered as part of a screening algorithm for early identification of 
malignancy. We correlate elevated platelet levels at the diagnosis of malignancy 
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with decreased interval to progression and decreased overall survival. We 
provide evidence that normalization of platelet levels reflects relative success of 
therapy, and we provide evidence that elevation of platelet levels during the post-
therapy monitoring period may be useful as part of a monitoring program. Historic 
evidence would suggest that ovarian cancer patients who have normalized CA-
125 and negative imaging at the conclusion of induction therapy continue to have 
up to a 50% rate of persistent disease. And, in the case of ovarian cancer, recent 
prospective data has raised concern that CA-125 monitoring after the conclusion 
of therapy may not improve cancer-related outcomes. Given, in the case of 
ovarian cancer, that CA-125 has proven to be of at best controversial utility in 
monitoring disease, and given that the present data is weakened by its 
retrospective collection, we would advocate for the inclusion of CBC’s as part of 
a prospective monitoring program both during and after therapy in order to better 
identify patients with persistence of disease at the conclusion of therapy, but also 
in the hope of obtaining early identification of patients who may have a 
recurrence amenable to definitive therapy. 
 
 In the present work, we go beyond established literature on the effects of 
platelets on endothelial cells, and we show in multiple cell lines that platelets 
confer apoptosis resistance, increase rates of proliferation, and encourage the 
migration of tumor cells. Understanding that platelets are known to sequester and 
release multiple mitogens and regulators of angiogenesis, we were able to show 
via siRNA transfection and protein knock-down that at least a portion of the 
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observed effects on apoptosis were due to signaling through TGFBR1 and at 
least a portion of the proliferative effects were mediated through PDGFRA 
signaling. It is recognized that platelet activation results in the release of multiple 
mediators, and therefore we approached the question of therapy not from the 
perspective of attempting to block one or another pathway, but from the 
perspective of blocking platelet activation and release of the mediators in 
question.  
  
 A simplified schematic is offered in Figure 27. Briefly, the simplified model 
reflects a biology in which tumor is subjected to routine platelet trafficking as a 
result of characteristically haphazard and leaky vasculature. Platelets in the 
tumor are activated by various stimuli within the tumor, and this activation results 
in the release of mitogenic cytokines, including PDGFA and TGFB1, that lead to 
tumor proliferation, apoptosis resistance, and increased migration. We propose 
this process of co-opting the normal, wound-healing functions of platelets to be a 
routine part of tumor biology that contributes to the ability of tumor cells to survive 
in an adverse environment, to propagate in the body, and to metastasize.  
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Figure 27: A simplified model of co-opted platelet function contributing to tumor 
cell proliferation, survival, and metastatic potential. 
 
 
Recognizing that platelet activity is dependent on activation, we first 
demonstrated that platelet-mediated mitogenic functions, i.e. apoptosis 
resistance and proliferation, could be blocked simply by platelet fixation with 
paraformaldehyde. We were subsequently able to demonstrate that proliferative 
functions were able to be (at least partially) be blocked by co-culture in the 
context of aspirin and an inhibitor of FAK.  
 
 As part of the consideration of how platelets would interact with tumor as 
regulators of angiogenesis, we began or investigation in vitro with the use of an 
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induced hypoxic environment. We were able to demonstrate that hypoxia 
resulted in a 6-fold increase in ADP in the environment around tumor cells. It is 
important in consideration of this fact to recall that ADP is a powerful activator of 
platelets, and concentrations of ADP three orders of magnitude less than that 
seen in our experiments have been shown to activate platelets that have been 
treated with high doses of aspirin. Also, our work showed that platelets facilitate 
growth of tumor cells in the hypoxic environment in a manner visually identical to 
that seen in the normoxic environment, suggesting that platelet activity (that 
would be increased by ADP activation in a hypoxic micro-environment) may 
rescue cell populations from the stress imposed by hypoxia. It is important to 
recall that tumors have characteristically leaky vasculature, and our work 
demonstrated platelet transit into the bulk of tumor. 
 
 In order to test these hypotheses in a more typical biologic environment, 
we used orthotopic models of ovarian cancer in mice that are well known to our 
lab. In our first experiment, we showed that depletion of platelets using an anti-
platelet antibody had anti-tumor effects by itself, and depletion of platelets 
increased the efficacy of cytotoxic chemotherapy. In the next experiment, we 
showed that platelet transfusion had the opposite effect, increasing tumor growth 
and decreasing the efficacy of cytotoxic chemotherapy. After that, we attempted 
to block the effects of platelet transfusion with aspirin. Two interesting 
observations emerged. The first was that aspirin by itself seemed to have 
minimal effect in this model; in fact, pre-treatment of transfused platelets with 
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aspirin only partially blocked their effect on the tumor. Within this context, it is 
important to recall that an adequate amount of ADP will activate platelets despite 
aspirin therapy, and so many of these platelets may well have been activated in 
the tumor despite aspirin therapy. The second observation was that platelet 
transfusion was associated with increased proliferation of tumor cells, decreased 
apoptosis of tumor cells, and an increased frequency of lumina identified in 
vessels suggesting vascular stabilization, normalization, and maturation. Again, 
these effects were incompletely blocked by aspirin pre-treatment of transfused 
platelets. 
 
 These observations, coupled with the sheer magnitude of angiogenic 
mediators housed by platelets, to consider whether platelets may be at least 
partially responsible for the poor performance of angiogenic drugs in clinical trials 
and for emerging evidence of resistance to anti-angiogenic agents that has been 
described in recent literature. In order to consider this possibility, we first 
established a model system in vivo using short versus continuous treatment with 
anti-angiogenic agents. This model consistently demonstrated an acceleration of 
growth after short-term treatment with anti-angiogenic drugs, however variances 
and inadequate mouse numbers to meet strict statistical significance in many 
cases limited the model. Despite this limitation, we were able to in two cell lines 
and using two anti-angiogenic agents demonstrate that the acceleration in tumor 
growth seen after short-term anti-angiogenic therapy could be blocked by the use 
of the FAK-inhibitor. Recalling that platelets deficient in FAK signaling have 
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diminished capacity to spread and activate, and recalling our in vitro findings with 
respect to the FAK-inhibitor blocking platelet-mediated proliferation, we sought to 
establish that the effects of the FAK-inhibitor on the observed tumor growth were 
at least partially attributable to platelet-specific effects. We were able to offer 
preliminary evidence that that platelet infiltration into tumor is significantly 
increased given seven days of hypoxia-inducing anti-angiogenic therapy, 
supporting the hypothesis that local platelet activation is increased. 
 
 In view of these findings, we propose the following model to account for 
the effects of hypoxia, both biological resulting from tumor growth and iatrogenic 
from the use of anti-angiogenic therapy, in Figure 28. 
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Figure 28. The effect of tumor hypoxia on platelet trafficking and activation. 
 
 In this model, we propose that hypoxia results in an increase in local ADP 
in the tumor microenvironment that increases the capacity of the tumor to 
activate platelets. At the same time, increased vascular irregularity permits 
increased incidental trafficking of platelets. In fact, our preliminary data suggests 
that platelet levels may systemically increase as a result of tumor hypoxia, a 
result supported by data that tumor IL-6, which is known to drive malignant 
thrombocytosis, is produced in response to hypoxia. Platelet activation results in 
improved tumor angiogenesis and neovascularization, along with the increased 
proliferation, decreased apoptosis, and increased migratory behavior of tumor 
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cells already considered. This entire process can be slowed, or even stopped, 
with the use of agents such as aspirin and FAK-inhibitors that block activation. It 
is noted that FAK-inhibitors have the added benefit of slowing platelet migration 
in response to fibrinogen. 
 
 Better understanding of the full spectra of factors, especially those normal 
and co-opted, regulating angiogenesis and mitogenic behavior will necessarily 
lead not only to more effective treatment of angiogenesis specifically, but it may 
also lead to a better understanding of the most optimal dosing of various, more 
common, chemotherapeutic regimens. And increased understanding of the 
behavior of platelets as a mediator of angiogenesis should cause a 
reconsideration of the degree of thrombocytopenia that constitutes a toxicity of 
chemotherapy and what degree of thrombocytopenia might be seen as a 
desirable treatment effect. Similarly, it is appropriate to consider the broad 
ramifications of treatment effects of more traditional agents, not just on tumor 
cells specifically, but on other cells in the micro-environment. In the same way 
that taxanes have been show to impact platelet function beyond direct tumor 
effect, we have shown that inhibition of FAK impacts platelet function and the 
interaction of platelets with tumor above and beyond well-known direct tumor 
effect. Future attempts to understand and treat cancer may demand a greater 
emphasis on a systemic, ecological understanding of cancer and its context 
within the body. In this work, we consider the effects of platelets directly on tumor 
and within the context of angiogenic regulation necessary for tumor growth. We 
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demonstrate previously unknown mitogenic effects of platelets on tumor cells, we 
show that platelets and tumor cells interact, and we show that platelet-driven 
modulation of angiogenesis contributes to therapeutic resistance. 
 
 The current data argue strongly for consideration of the routine use of 
combination therapy when an anti-angiogenic agent is considered. Specifically, 
when considering anti-angiogenic therapy, one should consider adding agents 
that have anti-activation effects on platelets. Many of these drugs are already 
available on the market, such as aspirin, clopidogrel, and lovenox. FAK-
inhibitors, with the added benefit of limiting platelet migration, are entering clinical 
trials both as single agents and as combination therapy with anti-angiogenic 
agents. These data offer an additional biological rationale for this combination. 
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